<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" xml:lang="en" dtd-version="1.4"><front><journal-meta><journal-id journal-id-type="nlm-ta">Vaccines (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Vaccines (Basel)</journal-id><journal-id journal-id-type="pmc-domain-id">2764</journal-id><journal-id journal-id-type="pmc-domain">vaccines</journal-id><journal-id journal-id-type="publisher-id">vaccines</journal-id><journal-title-group><journal-title>Vaccines</journal-title></journal-title-group><issn pub-type="epub">2076-393X</issn><publisher><publisher-name>Multidisciplinary Digital Publishing Institute  (MDPI)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC7923097</article-id><article-id pub-id-type="pmcid-ver">PMC7923097.1</article-id><article-id pub-id-type="pmcaid">7923097</article-id><article-id pub-id-type="pmcaiid">7923097</article-id><article-id pub-id-type="pmid">33671124</article-id><article-id pub-id-type="doi">10.3390/vaccines9020162</article-id><article-id pub-id-type="publisher-id">vaccines-09-00162</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Strategies for Enhancement of Live-Attenuated <italic toggle="yes">Salmonella</italic>-Based Carrier Vaccine Immunogenicity</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Galen</surname><given-names initials="JE">James E.</given-names></name><xref ref-type="aff" rid="af1-vaccines-09-00162">1</xref><xref rid="c1-vaccines-09-00162" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-5623-1903</contrib-id><name name-style="western"><surname>Wahid</surname><given-names initials="R">Rezwanul</given-names></name><xref ref-type="aff" rid="af1-vaccines-09-00162">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Buskirk</surname><given-names initials="AD">Amanda D.</given-names></name><xref ref-type="aff" rid="af2-vaccines-09-00162">2</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name name-style="western"><surname>Sobrino</surname><given-names initials="F">Francisco</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-vaccines-09-00162"><label>1</label>Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD 21201, USA; <email>rwahid@som.umaryland.edu</email></aff><aff id="af2-vaccines-09-00162"><label>2</label>Center for Drug Evaluation and Research, Office of Pharmaceutical Quality, Office of Process and Facilities, Division of Microbiology Assessment II, U.S. Food and Drug Administration, Silver Spring, MD 20903, USA; <email>abuskirk02@gmail.com</email></aff><author-notes><corresp id="c1-vaccines-09-00162"><label>*</label>Correspondence: <email>jgalen@som.umaryland.edu</email></corresp></author-notes><pub-date pub-type="epub"><day>17</day><month>2</month><year>2021</year></pub-date><pub-date pub-type="collection"><month>2</month><year>2021</year></pub-date><volume>9</volume><issue>2</issue><issue-id pub-id-type="pmc-issue-id">376191</issue-id><elocation-id>162</elocation-id><history><date date-type="received"><day>15</day><month>1</month><year>2021</year></date><date date-type="accepted"><day>15</day><month>2</month><year>2021</year></date></history><pub-history><event event-type="pmc-release"><date><day>17</day><month>02</month><year>2021</year></date></event><event event-type="pmc-live"><date><day>03</day><month>03</month><year>2021</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-03-30 07:25:26.980"><day>30</day><month>03</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>&#169; 2021 by the authors.</copyright-statement><copyright-year>2021</copyright-year><license license-type="open-access"><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="vaccines-09-00162.pdf"/><abstract><p>The use of live-attenuated bacterial vaccines as carriers for the mucosal delivery of foreign antigens to stimulate the mucosal immune system was first proposed over three decades ago. This novel strategy aimed to induce immunity against at least two distinct pathogens using a single bivalent carrier vaccine. It was first tested using a live-attenuated <italic toggle="yes">Salmonella enterica</italic> serovar Typhi strain in clinical trials in 1984, with excellent humoral immune responses against the carrier strain but only modest responses elicited against the foreign antigen. Since then, clinical trials with additional <italic toggle="yes">Salmonella</italic>-based carrier vaccines have been conducted. As with the original trial, only modest foreign antigen-specific immunity was achieved in most cases, despite the incorporation of incremental improvements in antigen expression technologies and carrier design over the years. In this review, we will attempt to deconstruct carrier vaccine immunogenicity in humans by examining the basis of bacterial immunity in the human gastrointestinal tract and how the gut detects and responds to pathogens versus benign commensal organisms. Carrier vaccine design will then be explored to determine the feasibility of retaining as many characteristics of a pathogen as possible to elicit robust carrier and foreign antigen-specific immunity, while avoiding over-stimulation of unacceptably reactogenic inflammatory responses.</p></abstract><kwd-group><kwd>Salmonella</kwd><kwd>Typhi</kwd><kwd>carrier vaccine</kwd><kwd>immunogenicity</kwd><kwd>homeostasis</kwd><kwd>inflammation</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec1-vaccines-09-00162"><title>1. Introduction</title><p>The concept of bacterial-based carrier vaccines rests on the notion that an attenuated strain of bacteria, genetically engineered to be safe yet still immunogenic, can be further engineered by the introduction of additional genes encoding protective antigens from unrelated pathogens; the resulting multivalent candidate vaccine should then be capable of eliciting biologically relevant protective immune responses against both the carrier vaccine itself as well as the additional target pathogens. Although simple in principle and elegant in terms vaccine development, this novel approach has required refinement through various iterations over the last three decades, with testing in clinical trials yielding only limited success. In this review, we will re-examine the engineering of <italic toggle="yes">Salmonella enterica</italic>-based carrier vaccines with an eye towards optimizing protective efficacy while maintaining acceptable reactogenicity. We will first summarize the state-of-the-art for clinical trials conducted using carrier vaccines derived from <italic toggle="yes">S.</italic> Typhi. We will then attempt to deconstruct the lack of carrier vaccine immunogenicity in humans by examining the basis of bacterial immunity in the human gastrointestinal tract and how the gut detects and responds to pathogens. Carrier vaccine design will then be explored to determine the feasibility of retaining as many characteristics of a pathogen as possible to elicit robust carrier and foreign-antigen-specific immunity, while avoiding overstimulation of unacceptably reactogenic inflammatory responses. The insights gleaned from this discussion will provide a basis for possible solutions that may significantly improve the overall immunogenicity of <italic toggle="yes">S.</italic> Typhi-based carrier vaccines in humans.</p></sec><sec id="sec2-vaccines-09-00162"><title>2. A summary of <italic toggle="yes">S.</italic> Typhi-based Carrier Vaccine Performance in Clinical Trials</title><p>Since 1984, at least a dozen <italic toggle="yes">S.</italic> Typhi-based carrier vaccines have been tested in clinical trials, as summarized in <xref rid="vaccines-09-00162-t001" ref-type="table">Table 1</xref>. In general, these vaccines were derived from the fully virulent clinical isolate Ty2, which was attenuated by chromosomal deletions affecting critical metabolic pathways, as opposed to deletion(s) of chromosomally encoded virulence factors. The carrier strains delivered only a single foreign antigen, which was typically of prokaryotic origin and targeted pathogenic bacteria. In most cases, the foreign antigen was expressed from a multicopy plasmid that did not encode resistance to an antibiotic (typically included in plasmids for selection purposes, but currently discouraged from use in licensed human oral vaccines by the Food and Drug Administration). To ensure retention in vivo within carrier vaccines after mucosal immunization, most expression plasmids also encoded a balanced lethal system in which loss of the plasmid would result in lysis of the carrier vaccine. This prevents plasmid-less organisms from outgrowing carrier organisms and tilting adaptive immune responses away from the foreign antigen and towards the carrier strain itself. Where expression plasmids were not used, foreign-antigen-encoding gene cassettes were stably integrated into the chromosome, again assuring stability of expression while avoiding the use of antibiotics to select for expression. All volunteers in these trials were immunized mucosally, with most immunized orally and only one cohort receiving rectal immunization [<xref rid="B1-vaccines-09-00162" ref-type="bibr">1</xref>]. In general, the immunization strategy involved delivery only with the carrier strain, although vaccination by a heterologous prime&#8211;boost regime, in which volunteers first received the carrier strain orally and were then boosted intramuscularly with adjuvanted foreign antigen, has also been conducted.</p><p>Most reported clinical trials studying <italic toggle="yes">S.</italic> Typhi-based carrier vaccines have focused on foreign-antigen-specific humoral immunity rather than antigen-specific, cell-mediated immunity. However, few of these trials demonstrated foreign-antigen-specific seroconversions in the majority of volunteers, with many studies reporting percentages well below 25%. A successful clinical trial described by Bumann et al. in 2010 [<xref rid="B12-vaccines-09-00162" ref-type="bibr">12</xref>] illustrates many of the study design parameters summarized above. In this study, volunteers were primed with a single oral dose of attenuated CVD 908 carrier vaccine presenting a plasmid-encoded outer membrane protein fusion of two antigens from <italic toggle="yes">Pseudomonas aeruginosa</italic>; all volunteers were then boosted intramuscularly (i.m.) 4 weeks later with a single dose of alum-adjuvanted purified fusion protein. These vaccinees mounted <italic toggle="yes">P. aeruginosa</italic>-specific serum IgG responses comparable to subjects immunized with 3 i.m. doses of adjuvanted subunit vaccine alone; however, orally primed volunteers also mounted <italic toggle="yes">P. aeruginosa</italic>-specific mucosal pulmonary IgA responses that were not observed in subjects receiving only i.m. immunizations. Interestingly, in an additional cohort of volunteers vaccinated with live vector vaccines derived from the more attenuated licensed vaccine Ty21a, three oral priming doses in addition to the i.m. booster dose were required to elicit immune responses comparable to those of volunteers receiving only a single oral priming dose of CVD 908 plus i.m. boost [<xref rid="B12-vaccines-09-00162" ref-type="bibr">12</xref>]. Although this study convincingly illustrates the proof-of-principle for using carrier vaccines to immunize via the mucosa against unrelated pathogens, most human studies conducted thus far have not been as successful in eliciting both foreign-antigen-specific and carrier-specific immunity. To gain insights into mechanisms potentially influencing the immunogenicity of live oral <italic toggle="yes">Salmonella</italic>-based carrier vaccines and the antigens that they co-express, we will briefly step back to examine a broader question of how the human intestine regulates immunity against pathogens versus non-pathogenic bacteria in the gut.</p></sec><sec id="sec3-vaccines-09-00162"><title>3. Why Are Commensal Bacteria Tolerogenic?</title><p>The gastrointestinal tract supports an extensive diversity of commensal bacteria, with the highest colonization densities residing in the colon [<xref rid="B14-vaccines-09-00162" ref-type="bibr">14</xref>,<xref rid="B15-vaccines-09-00162" ref-type="bibr">15</xref>]. The steady state condition of the gastrointestinal immune system is tolerogenic, a baseline condition referred to as homeostasis, in which commensal bacteria are prevented from access to deep tissues but are not actively cleared from the gastrointestinal tract [<xref rid="B16-vaccines-09-00162" ref-type="bibr">16</xref>]. Homeostasis is beneficial to the host for several important reasons, including colonization resistance, whereby non-pathogenic normal microbiota reside in permissive niches within the gut and compete with incoming, potentially pathogenic organisms to obstruct colonization [<xref rid="B15-vaccines-09-00162" ref-type="bibr">15</xref>]. Colonization resistance against incoming pathogens is accomplished by a variety of mechanisms, including: (1) limitation of available nutrients, (2) metabolization of host bile salts into secondary bile salts with antibacterial properties, (3) secretion of antibacterial compounds such as bacteriocins and antimicrobial peptides, and (4) cell-to-cell inhibition through type 6 secretion systems (T6SS, [<xref rid="B17-vaccines-09-00162" ref-type="bibr">17</xref>]). A recent report suggests that maintenance of the phylogenetic diversity of commensal bacteria in the human gut also exerts a significant immunomodulatory effect to promote homeostasis by balancing the response to particularly immunostimulatory bacteria with other microbial species that dampen host immune responses [<xref rid="B18-vaccines-09-00162" ref-type="bibr">18</xref>].</p><p>The metabolism of resident human microflora also provides metabolites to the host that are not normally available from human metabolic activity, including the short-chain fatty acids (SCFAs) butyrate, propionate, and acetate [<xref rid="B19-vaccines-09-00162" ref-type="bibr">19</xref>]. SCFAs contribute to the maintenance of homeostasis in several ways, including lowering of gastrointestinal pH, enhancement of mucus secretion, and stimulating the upregulation of tight junctions in intestinal epithelial cells (IECs) [<xref rid="B20-vaccines-09-00162" ref-type="bibr">20</xref>]. Butyrate in particular plays an important role in homeostasis by stimulating intestinal dendritic cells to secrete IL-10 to promote an increase in tolerogenic T<sub>reg</sub> cells, thereby maintaining an important balance between immunosuppressive T<sub>reg</sub>s and effectors such as IL-17-secreting Th17 and Th1 effector cells to regulate inflammation [<xref rid="B20-vaccines-09-00162" ref-type="bibr">20</xref>,<xref rid="B21-vaccines-09-00162" ref-type="bibr">21</xref>].</p><p>The detailed mechanisms by which humans regulate inflammation and control mucosal immune responses against commensal bacteria to preserve homeostasis are not fully understood. The process of deciphering these pathways has been likened to the old parable of blind men in a room describing an elephant; descriptions will depend on where and what one is attempting to examine [<xref rid="B21-vaccines-09-00162" ref-type="bibr">21</xref>]. However, considerable progress has been made in recent years examining the role that various intestinal cells play in the regulation of this pivotal process. It is now well recognized that unregulated inflammatory and adaptive responses can lead to severe intestinal pathologies, including inflammatory bowel disease. Therefore, the human host ensures proper regulation of homeostasis on multiple physical and immunological levels.</p><p>Physical containment of commensal bacteria to prevent unrestricted access to deeper tissue immune inductive sites is accomplished by mucus layers which overlay a single cell layer of IECs covering the lamina propria, where other immune inductive cells reside [<xref rid="B14-vaccines-09-00162" ref-type="bibr">14</xref>]. A thin layer of mucus covers the small intestinal epithelial tissue, while two distinct layers of mucus cover the epithelial tissue of the colon. These layers of mucus serve to physically sequester commensal organisms from colonizing and activating cytokine signaling from IECs (<xref ref-type="fig" rid="vaccines-09-00162-f001">Figure 1</xref>A); the mucus also traps both secretory IgA and antimicrobial peptides secreted by IECs to prevent microbial overgrowth and maintain homeostasis [<xref rid="B15-vaccines-09-00162" ref-type="bibr">15</xref>]. The underlying IECs function as bidirectional gate keepers that transmit induction signals to underlying lamina propria innate immune cells and subsequently transport secretory IgA (SIgA) via polymeric immunoglobulin receptors (pIgRs) out into the mucus bed and intestinal lumen [<xref rid="B22-vaccines-09-00162" ref-type="bibr">22</xref>]. Secretion of SIgA can involve T-independent homeostatic responses, where the SIgA comprises low-affinity polyreactive antibodies that bind to a variety of commensal organism structures, including lipopolysaccharides, flagellin, and capsular polysaccharides; the mechanism by which these polyreactive antibodies are generated remains unknown [<xref rid="B23-vaccines-09-00162" ref-type="bibr">23</xref>]. T-dependent adaptive responses produce conventional high-affinity and antigen-specific antibodies generated in regional lymph node germinal centers by induction mechanisms resembling systemic responses [<xref rid="B23-vaccines-09-00162" ref-type="bibr">23</xref>]. Numerous potential biological functions for SIgA have been proposed, including immune exclusion of bacteria through entrapment in mucus and interference with motility, although scant in vivo data exist in support of any of these mechanisms.</p><p>The balance between commensal homeostasis and the induction of inflammatory reactions, accompanied by subsequent adaptive responses against pathogenic organisms, depends on the ratio of CD4<sup>+</sup> Foxp3<sup>+</sup> regulatory T cells (T<sub>regs</sub>) to stimulatory CD4<sup>+</sup> ROR&#947;t<sup>+</sup> helper T cells (Th17 cells) [<xref rid="B25-vaccines-09-00162" ref-type="bibr">25</xref>,<xref rid="B26-vaccines-09-00162" ref-type="bibr">26</xref>,<xref rid="B27-vaccines-09-00162" ref-type="bibr">27</xref>,<xref rid="B28-vaccines-09-00162" ref-type="bibr">28</xref>] and is strongly influenced by local antigen-presenting cells (APCs), including both resident macrophages and dendritic cells (<xref ref-type="fig" rid="vaccines-09-00162-f001">Figure 1</xref>A). Resident macrophages in the lamina propria that are intimately associated with IECs are typically non-inflammatory, non-migratory cells that respond to opportunistic invasion by non-pathogenic bacteria via phagocytosis and intracellular killing [<xref rid="B16-vaccines-09-00162" ref-type="bibr">16</xref>,<xref rid="B29-vaccines-09-00162" ref-type="bibr">29</xref>,<xref rid="B30-vaccines-09-00162" ref-type="bibr">30</xref>,<xref rid="B31-vaccines-09-00162" ref-type="bibr">31</xref>]. Different from other macrophages, these macrophages have low levels of surface toll-like receptors (TLRs) that normally respond to pathogen-associated microbial patterns (PAMPs) to elicit activation and secretion of inflammatory cytokines; therefore, non-inflammatory resident macrophages that phagocytose commensal bacteria do not become activated, but rather secrete IL10, which stabilizes surrounding tolerogenic T<sub>regs</sub> [<xref rid="B32-vaccines-09-00162" ref-type="bibr">32</xref>]. Dendritic cells residing in the lamina propria can also respond to opportunistic non-pathogenic bacteria, perhaps due to local damage of the epithelial barrier. In this case, however, dendritic cells are able to migrate from the lamina propria to regional lymphoid tissue, directly presenting antigen to B cells in a T-independent manner to stimulate secretion of low-affinity polyreactive SIgA antibody into the mucus [<xref rid="B33-vaccines-09-00162" ref-type="bibr">33</xref>] to bind to and immobilize commensal bacteria, and thereby prevent further breach of the intestinal barrier [<xref rid="B25-vaccines-09-00162" ref-type="bibr">25</xref>,<xref rid="B34-vaccines-09-00162" ref-type="bibr">34</xref>]. In mice, IgA-coated commensal organisms can be taken up by M cells in the Peyer&#8217;s patches of the small intestine and presented to underlying dendritic cells to elicit production of immunosuppressive IL-10 and stimulation of T<sub>regs</sub>, thereby maintaining antigen-specific, commensal-targeted homeostasis [<xref rid="B35-vaccines-09-00162" ref-type="bibr">35</xref>,<xref rid="B36-vaccines-09-00162" ref-type="bibr">36</xref>]. Non-activated dendritic cells migrating to regional lymph nodes also secrete retinoic acid and TGF-&#946;, leading to differentiation of na&#239;ve T cells into tolerogenic T<sub>regs</sub> expressing gut-homing &#945;<sub>4</sub>&#946;<sub>7</sub> and CCR9 surface markers that facilitate maintenance of gut homeostasis [<xref rid="B28-vaccines-09-00162" ref-type="bibr">28</xref>,<xref rid="B31-vaccines-09-00162" ref-type="bibr">31</xref>,<xref rid="B37-vaccines-09-00162" ref-type="bibr">37</xref>,<xref rid="B38-vaccines-09-00162" ref-type="bibr">38</xref>]. These T<sub>regs</sub> secrete TGF-&#946; and IL-10 to suppress Th17 cells and inflammation [<xref rid="B26-vaccines-09-00162" ref-type="bibr">26</xref>,<xref rid="B39-vaccines-09-00162" ref-type="bibr">39</xref>].</p><p>Despite the central importance of APCs in maintaining homeostasis versus adaptive immunity, there are several other subsets of intestinal cells that are important in distinguishing between non-pathogenic and pathogenic organisms. Perhaps not surprisingly, IECs play an important role in sensing the invasion of microbes. Flagellin appears to be one important signaling molecule which binds to TLR5. Importantly, TLR5 is expressed in the basolateral membrane of non-activated IECs rather than in the apical membrane, where the concentration of flagellin from commensal organisms would be highest [<xref rid="B33-vaccines-09-00162" ref-type="bibr">33</xref>,<xref rid="B40-vaccines-09-00162" ref-type="bibr">40</xref>,<xref rid="B41-vaccines-09-00162" ref-type="bibr">41</xref>]. This compartmentalization of TLRs ensures that activation of IECs will likely occur from invading organisms coming into contact with the basolateral membrane of IECs (rather than from incidental contact with commensal organisms), resulting in secretion of proinflammatory cytokines as well as antimicrobial peptides. Interestingly, TLR2 (activated by lipoprotein ligands) is expressed on the apical side of IECs [<xref rid="B22-vaccines-09-00162" ref-type="bibr">22</xref>] and may therefore encounter ligands from commensal bacteria; however, TLR2/MyD88 signaling of IECs induces the generation of T<sub>reg</sub>s [<xref rid="B21-vaccines-09-00162" ref-type="bibr">21</xref>], again avoiding unnecessary and potentially damaging inflammatory responses. Potentially pathogenic invading organisms which successfully penetrate the IEC barrier encounter underlying dendritic cells, resulting in migration of fully activated dendritic cells to regional lymph nodes to elicit T cell-dependent adaptive responses through induction of helper T cells, including Th17 cells, to tip the balance away from tolerance dominated by T<sub>regs</sub> [<xref rid="B42-vaccines-09-00162" ref-type="bibr">42</xref>,<xref rid="B43-vaccines-09-00162" ref-type="bibr">43</xref>].</p><p>Another population of immune cells that play an important role in the maintenance of homeostasis are innate lymphoid cells (ILCs), which do not express high-affinity antigen receptors [<xref rid="B44-vaccines-09-00162" ref-type="bibr">44</xref>]. ILC3s, an important subset of ILCs typically associated with IECs, are activated by secretion of IL-23 from dendritic cells that have been stimulated by commensal bacteria [<xref rid="B45-vaccines-09-00162" ref-type="bibr">45</xref>]. Activation of ILC3s induces secretion of IL-22, which, in turn, stimulates IECs to secrete antimicrobial peptides into the mucus as well as stimulating the repair of tight junctions to mitigate any potential breaches to the epithelial barrier [<xref rid="B16-vaccines-09-00162" ref-type="bibr">16</xref>,<xref rid="B22-vaccines-09-00162" ref-type="bibr">22</xref>,<xref rid="B45-vaccines-09-00162" ref-type="bibr">45</xref>]. In this way, commensal organisms are again prevented from penetration into deeper tissues to stimulate unnecessary adaptive immune responses. In the absence of epithelial tissue damage, IECs secrete IL-25, which suppresses ILC3-mediated release of IL-22 to prevent overexpression of antimicrobial peptides [<xref rid="B45-vaccines-09-00162" ref-type="bibr">45</xref>,<xref rid="B46-vaccines-09-00162" ref-type="bibr">46</xref>].</p><p>It is clear then that the maintenance of a symbiotic relationship with non-pathogenic bacteria in the gastrointestinal tract is preserved by intricate pathways of cytokine communication between IECs, ILCs, macrophages, and dendritic cells, with redundancy built in to ensure proper segregation of normal flora from immune inductive sites. Breach of these barriers by pathogenic organisms, equipped with an array of virulence factors capable of defeating primary defenses against infection, triggers innate inflammatory responses and full activation of dendritic cells, which migrate to regional lymph nodes to elicit robust induction of adaptive immunity.</p></sec><sec id="sec4-vaccines-09-00162"><title>4. Why Are Reactogenic Vaccines Highly Immunogenic?</title><p>In view of the preceding discussion, it becomes clear that one reason that pathogenic organisms trigger pathogen-specific adaptive immune responses involves the activation of inflammatory responses, which recruit innate immune cells such as systemic macrophages, neutrophils, and cytotoxic natural killer cells to the area of infection to rapidly begin phagocytosing and killing invading organisms while activating other antigen-presenting cells such as dendritic cells. The mechanisms controlling the level of immune response against a given bacterial organism depend on overlapping and complementary detection strategies capable of discriminating between non-pathogenic and pathogenic organisms to mount either a tolerogenic non-inflammatory response or to trigger more robust adaptive immunity, respectively. Indeed, a theory describing a series of immune checkpoints for scaling the threat of a microbial infringement has recently been advanced [<xref rid="B47-vaccines-09-00162" ref-type="bibr">47</xref>,<xref rid="B48-vaccines-09-00162" ref-type="bibr">48</xref>], for which some formal evidence in support of specific aspects of the theory is now accumulating.</p><p>These immune checkpoints can respond to five key properties of invading pathogens that have been postulated to influence the strength of an adaptive immune response through interaction with these checkpoints. The first property concerns the particulate nature of ligands associated with invading pathogens, which is proposed to signal a higher microbial threat to the host immune system than soluble ligands. This would imply that intact organisms possessing multiple cell-associated ligands to activate different pattern-recognition receptors (such as lipopolysaccharide activation of TLR4 or flagellin activation of TLR5) could result in robust activation of innate immune cells and subsequent pathogen-specific adaptive immunity by multiple signaling pathways [<xref rid="B49-vaccines-09-00162" ref-type="bibr">49</xref>]. Intact pathogens could also present a higher density of surface antigens directly to B cells, thereby eliciting higher antigen-specific antibody responses than soluble antigens [<xref rid="B50-vaccines-09-00162" ref-type="bibr">50</xref>]. Support for this mechanism of particulate antigens stimulating robust antigen-specific immunity has recently been reported by Kanekiyo et al. [<xref rid="B51-vaccines-09-00162" ref-type="bibr">51</xref>], who used synthetic nanoparticle-based vaccines to elicit protective immunity against the Epstein&#8211;Barr virus in a mouse model. These nanoparticles presented symmetrically arrayed copies of the cell-binding ectodomain of gp350 (the cell-binding surface glycoprotein of the virion) that elicited virus-specific neutralizing antibody titers 10&#8211;100 fold higher than levels raised by soluble antigen, and significantly protected against challenge [<xref rid="B51-vaccines-09-00162" ref-type="bibr">51</xref>]. Additional evidence has been reported by Micoli et al. [<xref rid="B52-vaccines-09-00162" ref-type="bibr">52</xref>], who compared humoral immunity in mice against lipopolysaccharide O-antigens from <italic toggle="yes">Salmonella enterica</italic> serovar Typhimurium presented to the immune system either as particulate purified outer membrane vesicles (OMVs) or as soluble conjugate vaccines in which the O-antigen was chemically conjugated to the hapten carrier protein CRM197. Particulate OMVs were able to induce higher O-antigen-specific IgG responses with broader IgG subclass and Ig isotype profiles than soluble glycoconjugates, accompanied by strong bactericidal activity and reduced bacterial colonization, in mice challenged with virulent <italic toggle="yes">S.</italic> Typhimurium strains. Importantly, OMVs did not require the use of adjuvants while non-adjuvanted glycoconjugates were not immunogenic [<xref rid="B52-vaccines-09-00162" ref-type="bibr">52</xref>].</p><p>The second property of invading pathogens proposed to affect adaptive immunity is viability. Live organisms elicit more robust immune responses than dead organisms. In this respect, mRNA may be a key signaling molecule for the presence of live microbial threats because it is normally degraded very quickly and is not present in high levels in non-living organisms. In support of this possibility, over a decade ago, it was first observed that the immunogenicity of killed bacteria could be raised to the level elicited by live-attenuated bacteria, both administered parenterally in equal dosing schedules, by supplementation of killed vaccine with purified mRNA [<xref rid="B53-vaccines-09-00162" ref-type="bibr">53</xref>]. Accumulating evidence in human antigen-presenting cells now suggests that bacterial mRNA can function as a molecular signal of increased threat by invading pathogens through the signaling of endosomal TLR8 and subsequent inflammasome activation [<xref rid="B54-vaccines-09-00162" ref-type="bibr">54</xref>].</p><p>The third property of invading pathogens affecting adaptive immunity concerns live organisms with pathogenic factors facilitating colonization and/or secretion of toxins, which elicit more robust inflammatory and adaptive immune responses than non-pathogenic organisms without these additional factors. Excellent summaries of pathogenic secretion systems and other virulence factors, specifically relating to enteric bacteria<italic toggle="yes">,</italic> have been previously reported and will not be recapitulated here [<xref rid="B55-vaccines-09-00162" ref-type="bibr">55</xref>,<xref rid="B56-vaccines-09-00162" ref-type="bibr">56</xref>,<xref rid="B57-vaccines-09-00162" ref-type="bibr">57</xref>,<xref rid="B58-vaccines-09-00162" ref-type="bibr">58</xref>]. However, in the case of <italic toggle="yes">Salmonella</italic> (including <italic toggle="yes">S.</italic> Typhi), expression of ancillary effector proteins such as SopB is capable of delaying inflammatory responses by interrupting the proper function of TLRs through interference with adapter proteins such as TIRAP, which is required to facilitate downstream signaling of activation pathways [<xref rid="B59-vaccines-09-00162" ref-type="bibr">59</xref>,<xref rid="B60-vaccines-09-00162" ref-type="bibr">60</xref>]. This activity highlights the benefit to <italic toggle="yes">Salmonella</italic> of avoiding early inflammatory responses that could delay or diminish infection and promote clearance by adaptive responses.</p><p>The last two properties of invading pathogens affecting immune responses involve invasion of host barriers, frequently initiated when endothelial tissue is breached, which triggers inflammatory reactions. This activity appears to influence the maintenance of non-invasive commensals in the gastrointestinal tract through immune homeostasis, as discussed above. However, deep tissue penetration into normally sterile sites, in which homeostasis does not occur, provides robust signaling for inflammatory and adaptive responses. The impact of these two properties on inflammatory responses is clearly illustrated in the case of gastrointestinal colonization with <italic toggle="yes">Bacteroides fragilis</italic>, an organism that displays both commensal and pathogenic behavior in the same human host (<xref ref-type="fig" rid="vaccines-09-00162-f001">Figure 1</xref>A,B). Certain sub-species of <italic toggle="yes">B. fragilis,</italic> designated as Enterotoxigenic <italic toggle="yes">B. fragilis</italic> (ETBF), carry a unique pathogenicity island (BfPAI) encoding a potent metalloprotease enterotoxin called <italic toggle="yes">Bacteroides fragilis</italic> toxin, or BFT [<xref rid="B24-vaccines-09-00162" ref-type="bibr">24</xref>]. Despite carrying BfPAI, ETBF can be detected as commensal organisms in the colon of healthy individuals displaying no obvious signs of disease [<xref rid="B61-vaccines-09-00162" ref-type="bibr">61</xref>,<xref rid="B62-vaccines-09-00162" ref-type="bibr">62</xref>]. It has been demonstrated that the two-component signal transduction system RprX/Y downregulates BFT to maintain intestinal homeostasis and prevent disease [<xref rid="B63-vaccines-09-00162" ref-type="bibr">63</xref>]. However, unknown environmental signals can activate secretion of BFT, leading to loss of commensalism and damage of the colonic epithelial barrier through enzymatic cleavage of epithelial tight junctions (<xref ref-type="fig" rid="vaccines-09-00162-f001">Figure 1</xref>B). The clinical outcome of this transformation includes secretory diarrhea, inflammatory colitis, and extraintestinal infections. </p><p>These five properties of invasive pathogens, proposed to stimulate immune checkpoints controlling innate and adaptive immunity, seem to explain why reactogenic live oral vaccines have historically generated the most highly immunogenic pathogen-specific immune responses, while over-attenuated candidate vaccine strains have not provided biologically relevant immunity. Vaccines able to induce sufficient inflammatory responses via multiple signaling pathways can elicit a robust adaptive immune response capable of conferring protection against disease, while over-attenuated strains may be quickly cleared by innate cells (such as non-inflammatory macrophages) without eliciting inflammation. However, achieving the proper balance between acceptable reactogenicity and protective immunogenicity has proven to be a very elusive goal for engineering appropriately attenuated <italic toggle="yes">Salmonella</italic> vaccines in general and <italic toggle="yes">Salmonella</italic>-based carrier vaccines in particular.</p></sec><sec id="sec5-vaccines-09-00162"><title>5. Balancing Attenuation and Immunogenicity in Carrier Vaccines</title><p>In addition to the ability to stimulate innate immunity, other critically important factors influence the quality of an adaptive immune response against carrier vaccines and the foreign antigen(s) that they present to the immune system. Based on data from both murine intranasal animal models [<xref rid="B64-vaccines-09-00162" ref-type="bibr">64</xref>,<xref rid="B65-vaccines-09-00162" ref-type="bibr">65</xref>,<xref rid="B66-vaccines-09-00162" ref-type="bibr">66</xref>] and clinical trials (see <xref rid="vaccines-09-00162-t001" ref-type="table">Table 1</xref>), the factors influencing immunity can be categorized into four main groups whose interactive relationships combine to collectively affect the type, specificity, and magnitude of the immune response (<xref rid="vaccines-09-00162-t002" ref-type="table">Table 2</xref>). Given that a number of different strategies can be either engineered or carefully chosen to minimize any detrimental influence that each of these factors may exert on carrier vaccine immunogenicity, we will focus our discussion here on key concepts, and refer the reader to excellent reviews published elsewhere for more detailed discussions of approaches that have shown significant promise in animal models for improving responses in clinical trials.</p><sec id="sec5dot1-vaccines-09-00162"><title>5.1. Parental Strain Factors</title><p>We hypothesize that retention of as many native characteristics of a given pathogen as possible, to elicit robust carrier and foreign-antigen-specific immunity while avoiding over-stimulation of unacceptably reactogenic inflammatory responses, is essential to the development of an immunogenic carrier vaccine. In the case of <italic toggle="yes">S.</italic> Typhi-derived carrier vaccines, we reason that limited invasion of gastrointestinal tissue, facilitated by retention of multiple virulence factors of <italic toggle="yes">S.</italic> Typhi, will result in the vaccine reaching immune inductive sites in numbers sufficient to trigger an innate immune response that triggers adaptive immune responses, without high levels of replicating organisms precipitating more serious inflammatory reactions. This delicate balance between minimal reactogenicity through attenuation and robust immunogenicity can be achieved through chromosomal deletion of two types of genetic loci: 1) deletion of critical genes with pleiotropic effects on the expression of multiple factors essential to survival within the host, or 2) deletions which interrupt metabolic pathways to restrict the replication of vaccines within the host. Examples of carrier vaccines in which pleiotropic deletion mutations resulted in clinically acceptable attenuated vaccine candidates include deletions of <italic toggle="yes">phoP/phoQ</italic> (Ty1033, [<xref rid="B8-vaccines-09-00162" ref-type="bibr">8</xref>]), <italic toggle="yes">ssaV</italic> (TSB7, [<xref rid="B11-vaccines-09-00162" ref-type="bibr">11</xref>]), and <italic toggle="yes">htrA</italic> (CVD 908-<italic toggle="yes">htrA</italic>; [<xref rid="B7-vaccines-09-00162" ref-type="bibr">7</xref>,<xref rid="B67-vaccines-09-00162" ref-type="bibr">67</xref>,<xref rid="B68-vaccines-09-00162" ref-type="bibr">68</xref>]); all of these attenuated strains can no longer establish systemic infections within the host, which eventually leads to the classic pyrogenic state typical of typhoid fever. Examples of attenuating strategies which compromise the metabolic fitness of the candidate vaccine strain include deletion of &#916;<italic toggle="yes">aroC</italic>&#916;<italic toggle="yes">aroD</italic> (CVD 908, [<xref rid="B12-vaccines-09-00162" ref-type="bibr">12</xref>,<xref rid="B69-vaccines-09-00162" ref-type="bibr">69</xref>]) and &#916;<italic toggle="yes">cya</italic>&#916;<italic toggle="yes">crp</italic> (&#8220;chi strains&#8221;, [<xref rid="B13-vaccines-09-00162" ref-type="bibr">13</xref>,<xref rid="B70-vaccines-09-00162" ref-type="bibr">70</xref>]). In this regard, it should be emphasized that vaccine strains attenuated through compromised metabolic pathways maintain a full complement of virulence genes, which could result in unacceptable systemic infection with insufficiently attenuated vaccine candidates. This point is illustrated in the development of the vaccine strain CVD 908-<italic toggle="yes">htrA</italic>, in which the first iteration of the vaccine, CVD 908, was attenuated only with the deletions of <italic toggle="yes">aroC</italic> and <italic toggle="yes">aroD</italic>, resulting in the inability to synthesize aromatic amino acids and purines. Clinical trials with CVD 908 resulted in the detection of vaccine organisms in the blood (vaccinemia) of volunteers receiving a single oral dose containing 10<sup>7</sup> viable organisms [<xref rid="B67-vaccines-09-00162" ref-type="bibr">67</xref>]; introduction of the further deletion of <italic toggle="yes">htrA</italic>, a stress protein, prevented vaccinemia while maintaining robust humoral and cellular immune responses against the vaccine strain [<xref rid="B67-vaccines-09-00162" ref-type="bibr">67</xref>,<xref rid="B68-vaccines-09-00162" ref-type="bibr">68</xref>].</p><p>In contrast to under-attenuated vaccine strains, over-attenuation of vaccine strains can result in candidates that prove completely safe and non-reactogenic in subjects but also fail to elicit immunogenic responses to either the carrier itself or the foreign antigen [<xref rid="B71-vaccines-09-00162" ref-type="bibr">71</xref>]. However, in some cases, this drop in immunity can be overcome by increasing the number of doses administered. This point is clearly illustrated in clinical trials of carrier vaccines derived from CVD 908-<italic toggle="yes">htrA</italic> and Ty21a. Ty21a is a licensed typhoid live vaccine derived from the wild-type clinical isolate Ty2 by treatment with a chemical mutagen, resulting in multiple attenuating chromosomal lesions [<xref rid="B72-vaccines-09-00162" ref-type="bibr">72</xref>,<xref rid="B73-vaccines-09-00162" ref-type="bibr">73</xref>]; in contrast, CVD 908-<italic toggle="yes">htrA</italic> is a genetically engineered vaccine candidate in which only three precise deletion mutations have been introduced into Ty2 [<xref rid="B67-vaccines-09-00162" ref-type="bibr">67</xref>]. In clinical trials of CVD 908-<italic toggle="yes">htrA</italic> and Ty21a carrier vaccines expressing the urease foreign antigen from <italic toggle="yes">Helicobacter pylori</italic>, three doses of the Ty21a carrier containing 10<sup>10</sup> viable organisms were required to elicit urease-specific humoral immunity comparable to levels elicited by CVD 908-<italic toggle="yes">htrA</italic> administered in a single dose of 10<sup>8</sup> viable organisms [<xref rid="B12-vaccines-09-00162" ref-type="bibr">12</xref>]. These data suggest that in cases where the carrier strain may be over-attenuated and elicits insufficient immunity after a single dose, foreign-antigen-specific immunogenicity can be improved either by increasing the number of doses administered or by boosting with adjuvanted antigen. However, in cases where expression of the foreign antigen proves toxic to an already optimally attenuated and clinically acceptable vaccine strain, increasing the number of doses administered is not likely to overcome such a severe drop in fitness. The resulting over-attenuation would result in rapid clearance of vaccine organisms, insufficient activation of innate and humoral immunity, and insufficient levels of foreign antigen ultimately being delivered to the adaptive immune system to elicit antigen-specific immunity [<xref rid="B71-vaccines-09-00162" ref-type="bibr">71</xref>]. </p></sec><sec id="sec5dot2-vaccines-09-00162"><title>5.2. Antigen Expression Factors</title><p>Since the first clinical trials conducted with carrier vaccines in the 1980s [<xref rid="B2-vaccines-09-00162" ref-type="bibr">2</xref>,<xref rid="B3-vaccines-09-00162" ref-type="bibr">3</xref>,<xref rid="B4-vaccines-09-00162" ref-type="bibr">4</xref>], significant efforts have been invested in technologies for optimizing the expression levels of foreign antigens to stimulate biologically relevant immunity, including either mucosal, humoral, or cellular immune responses [<xref rid="B71-vaccines-09-00162" ref-type="bibr">71</xref>,<xref rid="B74-vaccines-09-00162" ref-type="bibr">74</xref>,<xref rid="B75-vaccines-09-00162" ref-type="bibr">75</xref>,<xref rid="B76-vaccines-09-00162" ref-type="bibr">76</xref>,<xref rid="B77-vaccines-09-00162" ref-type="bibr">77</xref>]. It is well appreciated that carrier vaccines derived from attenuated <italic toggle="yes">S.</italic> Typhi are fully capable of eliciting mucosal, humoral, and cellular responses after oral immunization in humans [<xref rid="B78-vaccines-09-00162" ref-type="bibr">78</xref>,<xref rid="B79-vaccines-09-00162" ref-type="bibr">79</xref>,<xref rid="B80-vaccines-09-00162" ref-type="bibr">80</xref>,<xref rid="B81-vaccines-09-00162" ref-type="bibr">81</xref>]. However, the design of carrier vaccines presents unique challenges posed directly by expression of the foreign antigen that are not encountered in the engineering of attenuated parental vaccines per se. In addition to the potential toxicity of a given foreign antigen when expressed in a carrier vaccine, which can directly interfere with the viability of the strain [<xref rid="B82-vaccines-09-00162" ref-type="bibr">82</xref>,<xref rid="B83-vaccines-09-00162" ref-type="bibr">83</xref>], inappropriate expression of high levels of an otherwise tolerable foreign antigen can stress the metabolic fitness of a carrier vaccine [<xref rid="B84-vaccines-09-00162" ref-type="bibr">84</xref>,<xref rid="B85-vaccines-09-00162" ref-type="bibr">85</xref>,<xref rid="B86-vaccines-09-00162" ref-type="bibr">86</xref>,<xref rid="B87-vaccines-09-00162" ref-type="bibr">87</xref>]. We have written extensively on this topic and will not recapitulate detailed arguments herein, but rather refer the reader to more extensive discussions of mechanisms published elsewhere [<xref rid="B71-vaccines-09-00162" ref-type="bibr">71</xref>,<xref rid="B74-vaccines-09-00162" ref-type="bibr">74</xref>,<xref rid="B75-vaccines-09-00162" ref-type="bibr">75</xref>]. Here, we emphasize that inappropriately high expression levels of foreign antigens create a physiological burden on a vaccine strain. This reduction in fitness is functionally equivalent to over-attenuation of the vaccine strain, reducing both the replication of these organisms and their ability to reach immune inductive sites at sufficient levels to elicit both innate and adaptive immunity.</p><p>Over-attenuation of carrier vaccines due to the metabolic burden associated with inappropriate expression of foreign antigens often occurs when these antigens are expressed from plasmids of high copy number [<xref rid="B88-vaccines-09-00162" ref-type="bibr">88</xref>]. This potential problem can be overcome both by varying the strength of the promoter controlling transcription of the foreign gene, as well as using tightly regulated plasmids with inherently low copy numbers. A particularly elegant choice of regulated promoters involves the use of promoters which are activated in the presence of environmental signals likely to be encountered in the host after oral immunization, such as osmolarity [<xref rid="B88-vaccines-09-00162" ref-type="bibr">88</xref>], oxygen tension [<xref rid="B89-vaccines-09-00162" ref-type="bibr">89</xref>], and environmental shock [<xref rid="B89-vaccines-09-00162" ref-type="bibr">89</xref>]. However, plasmid-based expression of foreign antigens exerts metabolic pressure on the carrier vaccine that can induce the spontaneous loss of the plasmid in vivo to improve growth rate. For this reason, &#8220;balanced lethal&#8221; strategies have been employed to prevent spontaneous plasmid loss which would obliterate foreign antigen-specific immunity [<xref rid="B90-vaccines-09-00162" ref-type="bibr">90</xref>,<xref rid="B91-vaccines-09-00162" ref-type="bibr">91</xref>]. Of note, these balanced lethal systems do not rely on the use of antibiotic resistance genes for introduction of expression plasmids into carrier vaccines, which also avoids the unintended spread of such resistance genes to other gastrointestinal organisms. The strategy behind balanced lethal plasmid retention involves essential factors encoded for on the expression plasmid which have been deleted from the bacterial chromosome; therefore, loss of the plasmid destroys the ability to synthesize the essential factor required for growth and the plasmid-less vaccine organisms are removed from the growing population. To date, balanced lethal systems based on <italic toggle="yes">thyA</italic> [<xref rid="B5-vaccines-09-00162" ref-type="bibr">5</xref>,<xref rid="B9-vaccines-09-00162" ref-type="bibr">9</xref>,<xref rid="B10-vaccines-09-00162" ref-type="bibr">10</xref>,<xref rid="B12-vaccines-09-00162" ref-type="bibr">12</xref>], <italic toggle="yes">asd</italic> [<xref rid="B1-vaccines-09-00162" ref-type="bibr">1</xref>,<xref rid="B13-vaccines-09-00162" ref-type="bibr">13</xref>]<italic toggle="yes">,</italic> and <italic toggle="yes">purB</italic> [<xref rid="B8-vaccines-09-00162" ref-type="bibr">8</xref>] have been evaluated in clinical trials with varying degrees of success. To avoid both plasmid instability issues and overexpression of foreign antigens, investigators have also chosen to integrate foreign gene cassettes into the chromosome of the carrier vaccine, again with varying degrees of success in clinical trials [<xref rid="B6-vaccines-09-00162" ref-type="bibr">6</xref>,<xref rid="B11-vaccines-09-00162" ref-type="bibr">11</xref>]; the drop in gene dosage of the foreign gene can result in a further drop in the level of foreign antigen synthesized and presented to the immune system, again leading to carrier vaccine failure.</p><p>Yet another issue that must be grappled with is the stability of the foreign antigen once synthesized by the carrier vaccine. Data from murine models of immunogenicity strongly suggest that surface expressed antigen, or antigen secreted from a <italic toggle="yes">Salmonella</italic>-based carrier vaccine into the surrounding milieu, is significantly more immunogenic than cytoplasmically expressed antigen that may aggregate into insoluble inclusion bodies or be degraded by proteases [<xref rid="B71-vaccines-09-00162" ref-type="bibr">71</xref>]. A number of promising antigen export systems have been tested in animal models [<xref rid="B92-vaccines-09-00162" ref-type="bibr">92</xref>,<xref rid="B93-vaccines-09-00162" ref-type="bibr">93</xref>,<xref rid="B94-vaccines-09-00162" ref-type="bibr">94</xref>,<xref rid="B95-vaccines-09-00162" ref-type="bibr">95</xref>,<xref rid="B96-vaccines-09-00162" ref-type="bibr">96</xref>,<xref rid="B97-vaccines-09-00162" ref-type="bibr">97</xref>,<xref rid="B98-vaccines-09-00162" ref-type="bibr">98</xref>,<xref rid="B99-vaccines-09-00162" ref-type="bibr">99</xref>,<xref rid="B100-vaccines-09-00162" ref-type="bibr">100</xref>], but to date, only one clinical trial has been conducted in which the foreign antigen was designed to be secreted [<xref rid="B13-vaccines-09-00162" ref-type="bibr">13</xref>]. Although exported from multicopy expression plasmids, volunteers failed to mount antigen-specific antibody responses against <italic toggle="yes">Streptococcus pneumonia</italic> surface protein A (PspA). The authors of this study speculated that poor growth of the vaccine in vivo, perhaps due to hyperattenuation, may not have permitted sufficient synthesis of PspA to stimulate immunity, again emphasizing the strict requirement for the carrier vaccine to reach immune inductive sites in sufficient numbers to elicit biologically relevant immune responses [<xref rid="B13-vaccines-09-00162" ref-type="bibr">13</xref>].</p><p>Supposing that one is able to adjust stable but sufficient expression levels of a foreign antigen while avoiding over-attenuation, an additional property impacting on antigen-specific immunity is the inherent immunogenicity of the antigen itself. This parameter is clearly observed in clinical trials of carrier vaccines expressing either the urease virulence factor from <italic toggle="yes">Helicobacter pylori</italic> [<xref rid="B9-vaccines-09-00162" ref-type="bibr">9</xref>,<xref rid="B10-vaccines-09-00162" ref-type="bibr">10</xref>] or a fusion protein of the outer membrane proteins OprF and OprI from <italic toggle="yes">Pseudomonas aeruginosa</italic> [<xref rid="B12-vaccines-09-00162" ref-type="bibr">12</xref>]. Recognizing the inherent uncertainty associated with comparing results from independently conducted clinical trials, we note that the same licensed vaccine Ty21a was used as the carrier strain in both studies. Both UreAB and OprF-OprI proteins were expressed from similar <italic toggle="yes">thyA</italic>-stabilized expression plasmids with medium copy numbers as well, and subjects received three oral doses of ~10<sup>10</sup> viable organisms per dose in both studies. However, for subjects immunized with Ty21a expressing UreAB, 0/9 volunteers developed antigen-specific IgG responses, although rises in cell-mediated immunity were noted. In contrast, 15/16 volunteers receiving Ty21a expressing OprF-OprI seroconverted. To further emphasize this point, 13/16 volunteers seroconverted after receiving three doses of 100-fold less viable CVD 908-<italic toggle="yes">htrA</italic> organisms (i.e., 10<sup>8</sup> viable organisms per dose) and developed antibodies against OprF-OprI expressed from the identical <italic toggle="yes">thyA</italic>-stabilized expression plasmid in the same study [<xref rid="B12-vaccines-09-00162" ref-type="bibr">12</xref>]. These observations underscore the notion that despite an optimally engineered carrier vaccine, choice of the target foreign antigen remains crucial to the ultimate success of the vaccine, despite the number of doses administered.</p></sec><sec id="sec5dot3-vaccines-09-00162"><title>5.3. Immunization Strategies</title><p>Clinical trials have proven essential for working out an effective immunization strategy, capable of eliciting robust and biologically relevant immunity against foreign antigens delivered to the immune system after oral inoculation. Of the trials conducted to date, both single and multiple dosing schedules have been tested (<xref rid="vaccines-09-00162-t001" ref-type="table">Table 1</xref>), with several important observations becoming clear from these studies. Contrary to data from mice orally immunized with <italic toggle="yes">Salmonella</italic>-based carrier vaccines [<xref rid="B101-vaccines-09-00162" ref-type="bibr">101</xref>,<xref rid="B102-vaccines-09-00162" ref-type="bibr">102</xref>,<xref rid="B103-vaccines-09-00162" ref-type="bibr">103</xref>,<xref rid="B104-vaccines-09-00162" ref-type="bibr">104</xref>], repeated oral immunization of humans does not reduce foreign-antigen-specific immune responses due to immunity elicited against the <italic toggle="yes">S.</italic> Typhi-based carrier strain itself, which could theoretically reduce the numbers of organisms reaching immune inductive sites. Indeed, in studies conducted by T.F. Meyer and colleagues [<xref rid="B9-vaccines-09-00162" ref-type="bibr">9</xref>,<xref rid="B10-vaccines-09-00162" ref-type="bibr">10</xref>], it was shown that priming subjects with the empty vaccine strain itself actually improved foreign-antigen-specific cellular immune responses elicited after oral boosting with the carrier vaccine expressing the targeted foreign protein. It has been repeatedly demonstrated in clinical trials that <italic toggle="yes">S.</italic> Typhi-specific immunity elicited by repeated dosing of volunteers with a carrier vaccine has minimal effects on foreign-antigen-specific immunity, even in cases where doses as high as 10<sup>10</sup> viable counts are given. This observation also appears to be independent of the spacing between doses, wherein neither administration of three doses within an 8-day period [<xref rid="B2-vaccines-09-00162" ref-type="bibr">2</xref>,<xref rid="B3-vaccines-09-00162" ref-type="bibr">3</xref>,<xref rid="B4-vaccines-09-00162" ref-type="bibr">4</xref>,<xref rid="B5-vaccines-09-00162" ref-type="bibr">5</xref>,<xref rid="B6-vaccines-09-00162" ref-type="bibr">6</xref>,<xref rid="B9-vaccines-09-00162" ref-type="bibr">9</xref>,<xref rid="B10-vaccines-09-00162" ref-type="bibr">10</xref>,<xref rid="B12-vaccines-09-00162" ref-type="bibr">12</xref>] or two doses separated by up to 56 days [<xref rid="B1-vaccines-09-00162" ref-type="bibr">1</xref>,<xref rid="B11-vaccines-09-00162" ref-type="bibr">11</xref>] exerted any effect on <italic toggle="yes">Salmonella</italic>-specific immunity; therefore, the strategy of multiple dosing to elicit optimum humoral or cellular immunity against foreign antigens appears to constitute a sound immunization strategy. This strategy becomes especially powerful in the context of first immunizing orally with one or more doses of <italic toggle="yes">S.</italic> Typhi carrier vaccine and then boosting parenterally with purified adjuvanted foreign antigen, an immunization regime referred to as heterologous prime-boosting and first explored for the improvement of malaria and HIV subunit vaccines [<xref rid="B105-vaccines-09-00162" ref-type="bibr">105</xref>,<xref rid="B106-vaccines-09-00162" ref-type="bibr">106</xref>]. Heterologous prime&#8211;boosting using <italic toggle="yes">S.</italic> Typhi carrier vaccines has been shown in murine intranasal models of immunogenicity to elicit excellent antigen-specific immunity, often superior to immunity elicited from multiple doses of carrier vaccine alone [<xref rid="B100-vaccines-09-00162" ref-type="bibr">100</xref>,<xref rid="B107-vaccines-09-00162" ref-type="bibr">107</xref>,<xref rid="B108-vaccines-09-00162" ref-type="bibr">108</xref>,<xref rid="B109-vaccines-09-00162" ref-type="bibr">109</xref>,<xref rid="B110-vaccines-09-00162" ref-type="bibr">110</xref>]. The success of this novel immunization strategy has also been confirmed in clinical trials [<xref rid="B12-vaccines-09-00162" ref-type="bibr">12</xref>], with excellent humoral immunity raised against the targeted foreign protein.</p></sec><sec id="sec5dot4-vaccines-09-00162"><title>5.4. Host Factors</title><p>In addition to factors influencing the antigen-specific immunity of carrier vaccines, one must also consider factors which can significantly affect the immunocompetence of the population intended to receive a given carrier vaccine. Given the complexity of mechanisms influencing immune function, a number of host-specific determinants should also be expected to affect the quality and specificity of an immune response to a carrier vaccine. Although the age of the individual and comorbidity status are two important determinants currently receiving significant attention (reviewed in [<xref rid="B111-vaccines-09-00162" ref-type="bibr">111</xref>,<xref rid="B112-vaccines-09-00162" ref-type="bibr">112</xref>,<xref rid="B113-vaccines-09-00162" ref-type="bibr">113</xref>,<xref rid="B114-vaccines-09-00162" ref-type="bibr">114</xref>], respectively), a thorough examination of these and other equally important determinants is beyond the scope of the current discussion. Rather, we limit our discussion to points relevant to the gastrointestinal tract and relating back to our analysis above of homeostasis.</p><p>It is now recognized that the immunogenicity of oral viral and bacterial vaccines administered to subjects in developing countries is significantly lower than immune responses observed for identical vaccines given in industrialized countries [<xref rid="B115-vaccines-09-00162" ref-type="bibr">115</xref>,<xref rid="B116-vaccines-09-00162" ref-type="bibr">116</xref>,<xref rid="B117-vaccines-09-00162" ref-type="bibr">117</xref>]. In low-income countries with unsanitary living conditions, people are often chronically exposed to contaminated food and water. As a result, adults and, in particular, malnourished children experience bacterial overgrowth of fecal organisms in the small intestine that are normally restricted to the colon of healthy individuals [<xref rid="B116-vaccines-09-00162" ref-type="bibr">116</xref>,<xref rid="B118-vaccines-09-00162" ref-type="bibr">118</xref>]. This leads to chronic histological changes in the small intestines, including blunting of villi and a prolonged inflammatory state that disrupts homeostasis, a condition referred to as environmental enteropathy [<xref rid="B119-vaccines-09-00162" ref-type="bibr">119</xref>,<xref rid="B120-vaccines-09-00162" ref-type="bibr">120</xref>]. The presence of fecal organisms outcompeting commensals in the small intestine can lead to a disruption of the intestinal mucosal barrier and systemic penetration of normal microbiota accompanied by endotoxemia [<xref rid="B117-vaccines-09-00162" ref-type="bibr">117</xref>].</p><p>The effects of environmental enteropathy on the immunogenicity of oral bacterial vaccines have been studied most extensively with oral cholera vaccines in clinical trials conducted in both developing and industrialized countries using the identical immunization protocols [<xref rid="B121-vaccines-09-00162" ref-type="bibr">121</xref>,<xref rid="B122-vaccines-09-00162" ref-type="bibr">122</xref>,<xref rid="B123-vaccines-09-00162" ref-type="bibr">123</xref>]. Landmark studies conducted with the live-attenuated cholera vaccine CVD 103-HgR clearly established that seroconversion rates after administration of a single oral dose were significantly higher in industrialized countries of North America and Europe than those observed in developing countries such as Peru, Chile, and Indonesia. It was noted that when the oral dose of viable organisms was increased 10-fold, seroconversion rates in developing countries significantly improved and approached rates seen with lower doses in industrialized populations [<xref rid="B121-vaccines-09-00162" ref-type="bibr">121</xref>]. A related phenomenon of lower reactogenicity of live vaccines in developing countries versus unacceptable reactogenicity observed with identical vaccines in industrialized settings was noted by Levine [<xref rid="B116-vaccines-09-00162" ref-type="bibr">116</xref>] with live-attenuated <italic toggle="yes">Shigella</italic> vaccines. In this study, low doses of attenuated organisms were required to avoid reactogenicity while still eliciting protective responses against experimental challenge in North American volunteers; when doses several logs higher were given to subjects in endemic regions of developing countries, neither reactogenicity nor immunogenicity were observed [<xref rid="B116-vaccines-09-00162" ref-type="bibr">116</xref>].</p><p>A leading hypothesis to explain this observation is that the mechanism behind reduced reactogenicity and immunogenicity of oral vaccines in developing countries relates to the chronic pro-inflammatory state of vaccinees, in which preexisting gut inflammation immediately clears incoming vaccine organisms, thereby preventing a sufficient number of organisms from reaching immune inductive sites [<xref rid="B116-vaccines-09-00162" ref-type="bibr">116</xref>]. It has also been hypothesized that the effect of fecal organisms reaching the blood of individuals leads to suppression of dendritic cells (antigen-presenting cells) and thereby lowering of the adaptive immune response [<xref rid="B116-vaccines-09-00162" ref-type="bibr">116</xref>,<xref rid="B117-vaccines-09-00162" ref-type="bibr">117</xref>]. Evidence for this hypothesis was reported by Hughes et al. [<xref rid="B124-vaccines-09-00162" ref-type="bibr">124</xref>], who documented reduced T cell activity and defects in dendritic cell activation in children that were linked to endotoxemia, accompanied by elevated levels of immunosuppressive IL-10; these &#8220;anergic&#8221; dendritic cells failed to support T cell proliferation, which would be expected to reduce adaptive immune responses to oral vaccination. Interestingly, as noted by Levine [<xref rid="B116-vaccines-09-00162" ref-type="bibr">116</xref>], these immunosuppressive effects in low-income regions are not observed with the live oral typhoid vaccine Ty21a. Levine hypothesized that the robust immunity elicited by Ty21a might be due to the unique ability of <italic toggle="yes">S.</italic> Typhi to quickly penetrate the gastrointestinal barrier and reach critical gut-associated lymphoid tissue to stimulate both innate and adaptive immunity. This potential characteristic of <italic toggle="yes">S.</italic> Typhi-based vaccines lends support to our previously stated proposition that the most immunogenic live-attenuated carrier vaccines will carry the lowest number of deleted virulence determinants, while at the same time conferring maximum safety and minimum reactogenicity to a clinically acceptable candidate vaccine. As we have pointed out in our discussion above, this balance can be achieved by strategic deletion of genes controlling essential metabolic pathways, the interruption of which prevents the synthesis of high enough levels of virulence determinants at the most permissive anatomical sites to circumvent immune surveillance and cause disease.</p></sec></sec><sec sec-type="conclusions" id="sec6-vaccines-09-00162"><title>6. Conclusions and Future Directions</title><p>We have explored the current state of carrier vaccine performance in clinical trials and have further discussed the influence of four key factors in determining immune responses against both the carrier strain itself and, perhaps more importantly, the foreign antigen (<xref rid="vaccines-09-00162-t001" ref-type="table">Table 1</xref> and <xref rid="vaccines-09-00162-t002" ref-type="table">Table 2</xref>). Although we have explored each of these factors independently, it is clear that the interrelationship between each factor will also affect the immunological outcome of oral vaccination with carriers. The importance of innate immunity was also highlighted as being important in eliciting a robust antigen-specific adaptive immune response, although the strength of the inflammatory response must not be overly strong so as to trigger unacceptable clinical reactions.</p><p>The clinical trials completed thus far have each provided important pieces of information essential to solving the puzzle of how to engineer and successfully test a highly immunogenic carrier vaccine against an unrelated human pathogen. Arguably, the most successful clinical trial conducted to date was reported by Bumann et al. [<xref rid="B12-vaccines-09-00162" ref-type="bibr">12</xref>], in which oral immunization with both licensed and experimental carrier vaccines compared favorably to parenteral immunization using multiple doses of an adjuvanted subunit vaccine. This important clinical trial took advantage of many optimized parameters for the factors (described above) affecting carrier vaccine immunogenicity, including:</p><p>(1) the choice of an attenuated <italic toggle="yes">S.</italic> Typhi parental strain that did not become over-attenuated upon expression of a foreign antigen and required only one dose for priming (parental strain factor);</p><p>(2) expression from genetically stabilized multicopy expression plasmids of sufficient foreign antigen to elicit biologically relevant immunity (antigen expression factors);</p><p>(3) use of a heterologous prime&#8211;boost strategy in which a single dose of carrier was followed by a single dose of adjuvanted subunit vaccine to elicit robust immunity (immunization factor);</p><p>(4) immunization of healthy North American adult volunteers (host factors).</p><p>We recognize that the use of North American volunteers may not be predictive of outcomes expected after oral delivery of candidate carrier vaccines in developing countries. This is possibly due to environmental enteropathy and therefore might only be considered as a &#8220;best possible case&#8221; for human immune responses when compared to target populations in endemic regions for which a given vaccine is intended. </p><p>Despite the promise of this clinical trial, several other considerations should be examined in the future to improve the utility of the carrier vaccine approach. Either secretion or surface expression of the foreign antigen should be explicitly examined in optimized carrier strains to further improve antigen-specific immunity. In addition, most previous trials have only examined humoral responses against the foreign antigen, although several trials reported by T.F. Meyer and colleagues [<xref rid="B9-vaccines-09-00162" ref-type="bibr">9</xref>,<xref rid="B10-vaccines-09-00162" ref-type="bibr">10</xref>] confirmed that oral priming with empty carrier strain followed by oral boosting with antigen-expressing carrier elicited significant cellular immunity against the foreign antigen. Therefore, a systematic examination of both humoral and cellular immunity against foreign protein targets could significantly advance the successful development of more immunogenic and protective carrier vaccines. Finally, no trial conducted to date has ever delivered more than one foreign antigen to the immune system; assuming that presentation of more than one protective antigen could significantly elevate protective efficacy without over-attenuating the carrier, it would be important to evaluate the immunogenicity of such a multivalent vaccine, followed by appropriate challenge, if such a challenge model was available.</p><p>Here, we have attempted to highlight promising technologies and approaches that might be exploited to improve the success of <italic toggle="yes">S.</italic> Typhi-based carriers as human vaccines. Although experimental animal models have proven essential to the initial design and pre-clinical testing of immunogenic carrier vaccines [<xref rid="B77-vaccines-09-00162" ref-type="bibr">77</xref>,<xref rid="B125-vaccines-09-00162" ref-type="bibr">125</xref>], it is ultimately human clinical trials that will definitively guide the development of <italic toggle="yes">S.</italic> Typhi-based carrier vaccines capable of eliciting robust protective efficacy against both <italic toggle="yes">S.</italic> Typhi and the unrelated foreign target pathogen as well. We have explored the retention of as many virulence properties of a candidate carrier vaccine as possible to elicit sufficient innate responses leading to robust adaptive immunity. However, we note that the strategies discussed here are not limited to enteric pathogens per se. These approaches can also be applied to non-pathogenic bacteria engineered as carrier vaccines; we refer the reader to other excellent reviews for a more in-depth examination of engineered non-pathogenic carrier vaccines [<xref rid="B126-vaccines-09-00162" ref-type="bibr">126</xref>,<xref rid="B127-vaccines-09-00162" ref-type="bibr">127</xref>]. Regardless of the type of carrier vaccine used, we look forward, with great optimism, to future results from well-designed clinical trials testing optimized carrier vaccines that incorporate the latest in genetic stabilization and gene expression technologies.</p></sec></body><back><fn-group><fn><p><bold>Publisher&#8217;s Note:</bold> MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><notes><title>Author Contributions</title><p>Conceptualization, J.E.G.; resources, J.E.G.; writing&#8212;original draft preparation, J.E.G., R.W., and A.D.B.; writing&#8212;review and editing, J.E.G., R.W., and A.D.B.; funding acquisition, J.E.G. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Funding</title><p>J.E.G. was supported in the preparation of this manuscript by grants from the National Institutes of Health, 1R01AI095309-01A1 and 1R56AI125388-01A1.</p></notes><notes><title>Institutional Review Board Statement</title><p>No statement from the IRB is required here.</p></notes><notes><title>Informed Consent Statement</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>Relevant data is found in the specific references mentioned.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflict of interest.</p></notes><ref-list><title>References</title><ref id="B1-vaccines-09-00162"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nardelli-Haefliger</surname><given-names>D.</given-names></name><name name-style="western"><surname>Kraehenbuhl</surname><given-names>J.-P.</given-names></name><name name-style="western"><surname>Curtiss</surname><given-names>R.</given-names><suffix>III</suffix></name><name name-style="western"><surname>Schodel</surname><given-names>F.</given-names></name><name name-style="western"><surname>Potts</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kelly</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>de Grandi</surname><given-names>P.</given-names></name></person-group><article-title>Oral and rectal immunization of adult female volunteers with a recombinant attenuated <italic toggle="yes">Salmonella typhi</italic> vaccine strain</article-title><source>Infect. Immun.</source><year>1996</year><volume>64</volume><fpage>5219</fpage><lpage>5224</lpage><pub-id pub-id-type="doi">10.1128/IAI.64.12.5219-5224.1996</pub-id><pub-id pub-id-type="pmid">8945569</pub-id><pub-id pub-id-type="pmcid">PMC174511</pub-id></element-citation></ref><ref id="B2-vaccines-09-00162"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tramont</surname><given-names>E.C.</given-names></name><name name-style="western"><surname>Chung</surname><given-names>R.</given-names></name><name name-style="western"><surname>Berman</surname><given-names>S.</given-names></name><name name-style="western"><surname>Keren</surname><given-names>D.</given-names></name><name name-style="western"><surname>Kapfer</surname><given-names>C.</given-names></name><name name-style="western"><surname>Formal</surname><given-names>S.B.</given-names></name></person-group><article-title>Safety and antigenicity of typhoid-<italic toggle="yes">Shigella sonnei</italic> vaccine (strain 5076-1C)</article-title><source>J. Infect. Dis.</source><year>1984</year><volume>149</volume><fpage>133</fpage><lpage>136</lpage><pub-id pub-id-type="doi">10.1093/infdis/149.2.133</pub-id><pub-id pub-id-type="pmid">6366077</pub-id></element-citation></ref><ref id="B3-vaccines-09-00162"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Black</surname><given-names>R.E.</given-names></name><name name-style="western"><surname>Levine</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Clements</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Losonsky</surname><given-names>G.</given-names></name><name name-style="western"><surname>Herrington</surname><given-names>D.</given-names></name><name name-style="western"><surname>Berman</surname><given-names>S.</given-names></name><name name-style="western"><surname>Formal</surname><given-names>S.B.</given-names></name></person-group><article-title>Prevention of shigellosis by a <italic toggle="yes">Salmonella typhi-Shigella sonnei</italic> bivalent vaccine</article-title><source>J. Infect. Dis.</source><year>1987</year><volume>155</volume><fpage>1260</fpage><lpage>1265</lpage><pub-id pub-id-type="doi">10.1093/infdis/155.6.1260</pub-id><pub-id pub-id-type="pmid">2437220</pub-id></element-citation></ref><ref id="B4-vaccines-09-00162"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Herrington</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Van De Verg</surname><given-names>L.</given-names></name><name name-style="western"><surname>Formal</surname><given-names>S.B.</given-names></name><name name-style="western"><surname>Hale</surname><given-names>T.L.</given-names></name><name name-style="western"><surname>Tall</surname><given-names>B.D.</given-names></name><name name-style="western"><surname>Cryz</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Tramont</surname><given-names>E.C.</given-names></name><name name-style="western"><surname>Levine</surname><given-names>M.M.</given-names></name></person-group><article-title>Studies in volunteers to evaluate candidate <italic toggle="yes">Shigella</italic> vaccines: Further experience with a bivalent <italic toggle="yes">Salmonella typhi-Shigella sonnei</italic> vaccine and protection conferred by previous <italic toggle="yes">Shigella sonnei</italic> disease</article-title><source>Vaccine</source><year>1990</year><volume>8</volume><fpage>353</fpage><lpage>357</lpage><pub-id pub-id-type="doi">10.1016/0264-410X(90)90094-3</pub-id><pub-id pub-id-type="pmid">2204243</pub-id></element-citation></ref><ref id="B5-vaccines-09-00162"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tacket</surname><given-names>C.O.</given-names></name><name name-style="western"><surname>Forrest</surname><given-names>B.</given-names></name><name name-style="western"><surname>Morona</surname><given-names>R.</given-names></name><name name-style="western"><surname>Attridge</surname><given-names>S.R.</given-names></name><name name-style="western"><surname>LaBrooy</surname><given-names>J.</given-names></name><name name-style="western"><surname>Tall</surname><given-names>B.D.</given-names></name><name name-style="western"><surname>Reymann</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rowley</surname><given-names>D.</given-names></name><name name-style="western"><surname>Levine</surname><given-names>M.M.</given-names></name></person-group><article-title>Safety, immunogenicity, and efficacy against cholera challenge in humans of a typhoid-cholera hybrid vaccine derived from <italic toggle="yes">Salmonella typhi</italic> Ty21a</article-title><source>Infect. Immun.</source><year>1990</year><volume>58</volume><fpage>1620</fpage><lpage>1627</lpage><pub-id pub-id-type="doi">10.1128/IAI.58.6.1620-1627.1990</pub-id><pub-id pub-id-type="pmid">1692807</pub-id><pub-id pub-id-type="pmcid">PMC258689</pub-id></element-citation></ref><ref id="B6-vaccines-09-00162"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gonzalez</surname><given-names>C.</given-names></name><name name-style="western"><surname>Hone</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Noriega</surname><given-names>F.</given-names></name><name name-style="western"><surname>Tacket</surname><given-names>C.O.</given-names></name><name name-style="western"><surname>Davis</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Losonsky</surname><given-names>G.</given-names></name><name name-style="western"><surname>Nataro</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Hoffman</surname><given-names>S.</given-names></name><name name-style="western"><surname>Malik</surname><given-names>A.</given-names></name><name name-style="western"><surname>Nardin</surname><given-names>E.</given-names></name></person-group><article-title><italic toggle="yes">Salmonella typhi</italic> vaccine strain CVD 908 expressing the circumsporozoite protein of <italic toggle="yes">Plasmodium falciparum</italic>: Strain construction and safety and immunogenicity in humans</article-title><source>J. Infect. Dis.</source><year>1994</year><volume>169</volume><fpage>927</fpage><lpage>931</lpage><pub-id pub-id-type="doi">10.1093/infdis/169.4.927</pub-id><pub-id pub-id-type="pmid">8133113</pub-id></element-citation></ref><ref id="B7-vaccines-09-00162"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tacket</surname><given-names>C.O.</given-names></name><name name-style="western"><surname>Galen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sztein</surname><given-names>M.B.</given-names></name><name name-style="western"><surname>Losonsky</surname><given-names>G.</given-names></name><name name-style="western"><surname>Wyant</surname><given-names>T.L.</given-names></name><name name-style="western"><surname>Nataro</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wasserman</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Edelman</surname><given-names>R.</given-names></name><name name-style="western"><surname>Chatfield</surname><given-names>S.</given-names></name><name name-style="western"><surname>Dougan</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Safety and immune responses to attenuated <italic toggle="yes">Salmonella enterica</italic> serovar Typhi oral live vector vaccines expressing tetanus toxin fragment C</article-title><source>Clin. Immunol.</source><year>2000</year><volume>97</volume><fpage>146</fpage><lpage>153</lpage><pub-id pub-id-type="doi">10.1006/clim.2000.4924</pub-id><pub-id pub-id-type="pmid">11027455</pub-id></element-citation></ref><ref id="B8-vaccines-09-00162"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>DiPetrillo</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Tibbetts</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kleanthous</surname><given-names>H.</given-names></name><name name-style="western"><surname>Killeen</surname><given-names>K.P.</given-names></name><name name-style="western"><surname>Hohmann</surname><given-names>E.L.</given-names></name></person-group><article-title>Safety and immunogenicity of <italic toggle="yes">phoP</italic>/<italic toggle="yes">phoQ</italic>-deleted <italic toggle="yes">Salmonella typhi</italic> expressing <italic toggle="yes">Helicobacter pylori</italic> urease in adult volunteers</article-title><source>Vaccine</source><year>1999</year><volume>18</volume><fpage>449</fpage><lpage>459</lpage><pub-id pub-id-type="doi">10.1016/S0264-410X(99)00246-7</pub-id><pub-id pub-id-type="pmid">10519934</pub-id></element-citation></ref><ref id="B9-vaccines-09-00162"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bumann</surname><given-names>D.</given-names></name><name name-style="western"><surname>Metzger</surname><given-names>W.G.</given-names></name><name name-style="western"><surname>Mansouri</surname><given-names>E.</given-names></name><name name-style="western"><surname>Palme</surname><given-names>O.</given-names></name><name name-style="western"><surname>Wendland</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hurwitz</surname><given-names>R.</given-names></name><name name-style="western"><surname>Haas</surname><given-names>G.</given-names></name><name name-style="western"><surname>Aebischer</surname><given-names>T.</given-names></name><name name-style="western"><surname>von Specht</surname><given-names>B.U.</given-names></name><name name-style="western"><surname>Meyer</surname><given-names>T.F.</given-names></name></person-group><article-title>Safety and immunogenicity of live recombinant <italic toggle="yes">Salmonella enterica</italic> serovar Typhi Ty21a expressing urease A and B from <italic toggle="yes">Helicobacter pylori</italic> in human volunteers</article-title><source>Vaccine</source><year>2001</year><volume>20</volume><fpage>845</fpage><lpage>852</lpage><pub-id pub-id-type="doi">10.1016/S0264-410X(01)00391-7</pub-id><pub-id pub-id-type="pmid">11738748</pub-id></element-citation></ref><ref id="B10-vaccines-09-00162"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Metzger</surname><given-names>W.G.</given-names></name><name name-style="western"><surname>Mansouri</surname><given-names>E.</given-names></name><name name-style="western"><surname>Kronawitter</surname><given-names>M.</given-names></name><name name-style="western"><surname>Diescher</surname><given-names>S.</given-names></name><name name-style="western"><surname>Soerensen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hurwitz</surname><given-names>R.</given-names></name><name name-style="western"><surname>Bumann</surname><given-names>D.</given-names></name><name name-style="western"><surname>Aebischer</surname><given-names>T.</given-names></name><name name-style="western"><surname>Von Specht</surname><given-names>B.U.</given-names></name><name name-style="western"><surname>Meyer</surname><given-names>T.F.</given-names></name></person-group><article-title>Impact of vector-priming on the immunogenicity of a live recombinant Salmonella enterica serovar typhi Ty21a vaccine expressing urease A and B from Helicobacter pylori in human volunteers</article-title><source>Vaccine</source><year>2004</year><volume>22</volume><fpage>2273</fpage><lpage>2277</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2003.11.020</pub-id><pub-id pub-id-type="pmid">15149786</pub-id></element-citation></ref><ref id="B11-vaccines-09-00162"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Chatfield</surname><given-names>S.</given-names></name><name name-style="western"><surname>Stratford</surname><given-names>R.</given-names></name><name name-style="western"><surname>Bedwell</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bentley</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sulsh</surname><given-names>S.</given-names></name><name name-style="western"><surname>Giemza</surname><given-names>R.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bongard</surname><given-names>E.</given-names></name><name name-style="western"><surname>Cosgrove</surname><given-names>C.A.</given-names></name><etal/></person-group><article-title>Ability of SPI2 mutant of <italic toggle="yes">S. typhi</italic> to effectively induce antibody responses to the mucosal antigen enterotoxigenic <italic toggle="yes">E. coli</italic> heat labile toxin B subunit after oral delivery to humans</article-title><source>Vaccine</source><year>2007</year><volume>25</volume><fpage>4175</fpage><lpage>4182</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2007.03.007</pub-id><pub-id pub-id-type="pmid">17412462</pub-id><pub-id pub-id-type="pmcid">PMC2652036</pub-id></element-citation></ref><ref id="B12-vaccines-09-00162"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bumann</surname><given-names>D.</given-names></name><name name-style="western"><surname>Behre</surname><given-names>C.</given-names></name><name name-style="western"><surname>Behre</surname><given-names>K.</given-names></name><name name-style="western"><surname>Herz</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gewecke</surname><given-names>B.</given-names></name><name name-style="western"><surname>Gessner</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>von Specht</surname><given-names>B.U.</given-names></name><name name-style="western"><surname>Baumann</surname><given-names>U.</given-names></name></person-group><article-title>Systemic, nasal and oral live vaccines against <italic toggle="yes">Pseudomonas aeruginosa</italic>: A clinical trial of immunogenicity in lower airways of human volunteers</article-title><source>Vaccine</source><year>2010</year><volume>28</volume><fpage>707</fpage><lpage>713</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2009.10.080</pub-id><pub-id pub-id-type="pmid">19887136</pub-id></element-citation></ref><ref id="B13-vaccines-09-00162"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Frey</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Lottenbach</surname><given-names>K.R.</given-names></name><name name-style="western"><surname>Hill</surname><given-names>H.</given-names></name><name name-style="western"><surname>Blevins</surname><given-names>T.P.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Brenneman</surname><given-names>K.E.</given-names></name><name name-style="western"><surname>Kelly-Aehle</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>McDonald</surname><given-names>C.</given-names></name><name name-style="western"><surname>Jansen</surname><given-names>A.</given-names></name><etal/></person-group><article-title>A Phase 1 dose-escalation trial in adults of three recombinant attenuated <italic toggle="yes">Salmonella</italic> Typhi vaccine vectors producing <italic toggle="yes">Streptococcus pneumoniae</italic> surface protein antigen PspA</article-title><source>Vaccine</source><year>2013</year><volume>31</volume><fpage>4874</fpage><lpage>4880</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2013.07.049</pub-id><pub-id pub-id-type="pmid">23916987</pub-id></element-citation></ref><ref id="B14-vaccines-09-00162"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mowat</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Agace</surname><given-names>W.W.</given-names></name></person-group><article-title>Regional specialization within the intestinal immune system</article-title><source>Nat. Rev. Immunol.</source><year>2014</year><volume>14</volume><fpage>667</fpage><lpage>685</lpage><pub-id pub-id-type="doi">10.1038/nri3738</pub-id><pub-id pub-id-type="pmid">25234148</pub-id></element-citation></ref><ref id="B15-vaccines-09-00162"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Donaldson</surname><given-names>G.P.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Mazmanian</surname><given-names>S.K.</given-names></name></person-group><article-title>Gut biogeography of the bacterial microbiota</article-title><source>Nat. Rev. Microbiol.</source><year>2016</year><volume>14</volume><fpage>20</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1038/nrmicro3552</pub-id><pub-id pub-id-type="pmid">26499895</pub-id><pub-id pub-id-type="pmcid">PMC4837114</pub-id></element-citation></ref><ref id="B16-vaccines-09-00162"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peterson</surname><given-names>L.W.</given-names></name><name name-style="western"><surname>Artis</surname><given-names>D.</given-names></name></person-group><article-title>Intestinal epithelial cells: Regulators of barrier function and immune homeostasis</article-title><source>Nat. Rev. Immunol.</source><year>2014</year><volume>14</volume><fpage>141</fpage><lpage>153</lpage><pub-id pub-id-type="doi">10.1038/nri3608</pub-id><pub-id pub-id-type="pmid">24566914</pub-id></element-citation></ref><ref id="B17-vaccines-09-00162"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sorbara</surname><given-names>M.T.</given-names></name><name name-style="western"><surname>Pamer</surname><given-names>E.G.</given-names></name></person-group><article-title>Interbacterial mechanisms of colonization resistance and the strategies pathogens use to overcome them</article-title><source>Mucosal. Immunol.</source><year>2019</year><volume>12</volume><fpage>1</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1038/s41385-018-0053-0</pub-id><pub-id pub-id-type="pmid">29988120</pub-id><pub-id pub-id-type="pmcid">PMC6312114</pub-id></element-citation></ref><ref id="B18-vaccines-09-00162"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Geva-Zatorsky</surname><given-names>N.</given-names></name><name name-style="western"><surname>Sefik</surname><given-names>E.</given-names></name><name name-style="western"><surname>Kua</surname><given-names>L.</given-names></name><name name-style="western"><surname>Pasman</surname><given-names>L.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>T.G.</given-names></name><name name-style="western"><surname>Ortiz-Lopez</surname><given-names>A.</given-names></name><name name-style="western"><surname>Yanortsang</surname><given-names>T.B.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Jupp</surname><given-names>R.</given-names></name><name name-style="western"><surname>Mathis</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Mining the Human Gut Microbiota for Immunomodulatory Organisms</article-title><source>Cell</source><year>2017</year><volume>168</volume><fpage>928</fpage><lpage>943.e11</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2017.01.022</pub-id><pub-id pub-id-type="pmid">28215708</pub-id><pub-id pub-id-type="pmcid">PMC7774263</pub-id></element-citation></ref><ref id="B19-vaccines-09-00162"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Daliri</surname><given-names>E.B.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>S.</given-names></name><name name-style="western"><surname>Oh</surname><given-names>D.H.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>B.H.</given-names></name></person-group><article-title>The human microbiome and metabolomics: Current concepts and applications</article-title><source>Crit. Rev. Food Sci. Nutr.</source><year>2017</year><volume>57</volume><fpage>3565</fpage><lpage>3576</lpage><pub-id pub-id-type="doi">10.1080/10408398.2016.1220913</pub-id><pub-id pub-id-type="pmid">27767329</pub-id></element-citation></ref><ref id="B20-vaccines-09-00162"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Iacob</surname><given-names>S.</given-names></name><name name-style="western"><surname>Iacob</surname><given-names>D.G.</given-names></name></person-group><article-title>Infectious Threats, the Intestinal Barrier, and Its Trojan Horse: Dysbiosis</article-title><source>Front. Microbiol.</source><year>2019</year><volume>10</volume><fpage>1676</fpage><pub-id pub-id-type="doi">10.3389/fmicb.2019.01676</pub-id><pub-id pub-id-type="pmid">31447793</pub-id><pub-id pub-id-type="pmcid">PMC6692454</pub-id></element-citation></ref><ref id="B21-vaccines-09-00162"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pandiyan</surname><given-names>P.</given-names></name><name name-style="western"><surname>Bhaskaran</surname><given-names>N.</given-names></name><name name-style="western"><surname>Zou</surname><given-names>M.</given-names></name><name name-style="western"><surname>Schneider</surname><given-names>E.</given-names></name><name name-style="western"><surname>Jayaraman</surname><given-names>S.</given-names></name><name name-style="western"><surname>Huehn</surname><given-names>J.</given-names></name></person-group><article-title>Microbiome Dependent Regulation of T(regs) and Th17 Cells in Mucosa</article-title><source>Front. Immunol.</source><year>2019</year><volume>10</volume><fpage>426</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2019.00426</pub-id><pub-id pub-id-type="pmid">30906299</pub-id><pub-id pub-id-type="pmcid">PMC6419713</pub-id></element-citation></ref><ref id="B22-vaccines-09-00162"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Goto</surname><given-names>Y.</given-names></name></person-group><article-title>Epithelial Cells as a Transmitter of Signals from Commensal Bacteria and Host Immune Cells</article-title><source>Front. Immunol.</source><year>2019</year><volume>10</volume><fpage>2057</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2019.02057</pub-id><pub-id pub-id-type="pmid">31555282</pub-id><pub-id pub-id-type="pmcid">PMC6724641</pub-id></element-citation></ref><ref id="B23-vaccines-09-00162"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bunker</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Bendelac</surname><given-names>A.</given-names></name></person-group><article-title>IgA Responses to Microbiota</article-title><source>Immunity</source><year>2018</year><volume>49</volume><fpage>211</fpage><lpage>224</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2018.08.011</pub-id><pub-id pub-id-type="pmid">30134201</pub-id><pub-id pub-id-type="pmcid">PMC6107312</pub-id></element-citation></ref><ref id="B24-vaccines-09-00162"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Valguarnera</surname><given-names>E.</given-names></name><name name-style="western"><surname>Wardenburg</surname><given-names>J.B.</given-names></name></person-group><article-title>Good Gone Bad: One Toxin Away From Disease for <italic toggle="yes">Bacteroides fragilis</italic></article-title><source>J. Mol. Biol.</source><year>2020</year><volume>432</volume><fpage>765</fpage><lpage>785</lpage><pub-id pub-id-type="doi">10.1016/j.jmb.2019.12.003</pub-id><pub-id pub-id-type="pmid">31857085</pub-id></element-citation></ref><ref id="B25-vaccines-09-00162"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Honda</surname><given-names>K.</given-names></name><name name-style="western"><surname>Littman</surname><given-names>D.R.</given-names></name></person-group><article-title>The microbiota in adaptive immune homeostasis and disease</article-title><source>Nature</source><year>2016</year><volume>535</volume><fpage>75</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.1038/nature18848</pub-id><pub-id pub-id-type="pmid">27383982</pub-id></element-citation></ref><ref id="B26-vaccines-09-00162"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>M.</given-names></name><name name-style="western"><surname>He</surname><given-names>C.</given-names></name><name name-style="western"><surname>Cong</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z.</given-names></name></person-group><article-title>Regulatory immune cells in regulation of intestinal inflammatory response to microbiota</article-title><source>Mucosal. Immunol.</source><year>2015</year><volume>8</volume><fpage>969</fpage><lpage>978</lpage><pub-id pub-id-type="doi">10.1038/mi.2015.49</pub-id><pub-id pub-id-type="pmid">26080708</pub-id><pub-id pub-id-type="pmcid">PMC4540654</pub-id></element-citation></ref><ref id="B27-vaccines-09-00162"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alroqi</surname><given-names>F.J.</given-names></name><name name-style="western"><surname>Chatila</surname><given-names>T.A.</given-names></name></person-group><article-title>T Regulatory Cell Biology in Health and Disease</article-title><source>Curr. Allergy Asthma Rep.</source><year>2016</year><volume>16</volume><fpage>27</fpage><pub-id pub-id-type="doi">10.1007/s11882-016-0606-9</pub-id><pub-id pub-id-type="pmid">26922942</pub-id><pub-id pub-id-type="pmcid">PMC5218767</pub-id></element-citation></ref><ref id="B28-vaccines-09-00162"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Omenetti</surname><given-names>S.</given-names></name><name name-style="western"><surname>Pizarro</surname><given-names>T.T.</given-names></name></person-group><article-title>The Treg/Th17 Axis: A Dynamic Balance Regulated by the Gut Microbiome</article-title><source>Front. Immunol.</source><year>2015</year><volume>6</volume><fpage>639</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2015.00639</pub-id><pub-id pub-id-type="pmid">26734006</pub-id><pub-id pub-id-type="pmcid">PMC4681807</pub-id></element-citation></ref><ref id="B29-vaccines-09-00162"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kmiec</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Cyman</surname><given-names>M.</given-names></name><name name-style="western"><surname>Slebioda</surname><given-names>T.J.</given-names></name></person-group><article-title>Cells of the innate and adaptive immunity and their interactions in inflammatory bowel disease</article-title><source>Adv. Med. Sci.</source><year>2017</year><volume>62</volume><fpage>1</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1016/j.advms.2016.09.001</pub-id><pub-id pub-id-type="pmid">28126697</pub-id></element-citation></ref><ref id="B30-vaccines-09-00162"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sanders</surname><given-names>T.J.</given-names></name><name name-style="western"><surname>Yrlid</surname><given-names>U.</given-names></name><name name-style="western"><surname>Maloy</surname><given-names>K.J.</given-names></name></person-group><article-title>Intestinal Mononuclear Phagocytes in Health and Disease</article-title><source>Microbiol Spectrum.</source><year>2017</year><pub-id pub-id-type="doi">10.1128/microbiolspec.MCHD-0047-2016</pub-id><pub-id pub-id-type="pmcid">PMC11687448</pub-id><pub-id pub-id-type="pmid">28102120</pub-id></element-citation></ref><ref id="B31-vaccines-09-00162"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Grainger</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Askenase</surname><given-names>M.H.</given-names></name><name name-style="western"><surname>Guimont-Desrochers</surname><given-names>F.</given-names></name><name name-style="western"><surname>da Fonseca</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Belkaid</surname><given-names>Y.</given-names></name></person-group><article-title>Contextual functions of antigen-presenting cells in the gastrointestinal tract</article-title><source>Immunol. Rev.</source><year>2014</year><volume>259</volume><fpage>75</fpage><lpage>87</lpage><pub-id pub-id-type="doi">10.1111/imr.12167</pub-id><pub-id pub-id-type="pmid">24712460</pub-id><pub-id pub-id-type="pmcid">PMC3992430</pub-id></element-citation></ref><ref id="B32-vaccines-09-00162"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bain</surname><given-names>C.C.</given-names></name><name name-style="western"><surname>Mowat</surname><given-names>A.M.</given-names></name></person-group><article-title>Macrophages in intestinal homeostasis and inflammation</article-title><source>Immunol. Rev.</source><year>2014</year><volume>260</volume><fpage>102</fpage><lpage>117</lpage><pub-id pub-id-type="doi">10.1111/imr.12192</pub-id><pub-id pub-id-type="pmid">24942685</pub-id><pub-id pub-id-type="pmcid">PMC4141699</pub-id></element-citation></ref><ref id="B33-vaccines-09-00162"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rossi</surname><given-names>O.</given-names></name><name name-style="western"><surname>van Baarlen</surname><given-names>P.</given-names></name><name name-style="western"><surname>Wells</surname><given-names>J.M.</given-names></name></person-group><article-title>Host-recognition of pathogens and commensals in the mammalian intestine</article-title><source>Curr. Top. Microbiol. Immunol.</source><year>2013</year><volume>358</volume><fpage>291</fpage><lpage>321</lpage><pub-id pub-id-type="pmid">22179258</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/82_2011_191</pub-id></element-citation></ref><ref id="B34-vaccines-09-00162"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Macpherson</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Uhr</surname><given-names>T.</given-names></name></person-group><article-title>Induction of protective IgA by intestinal dendritic cells carrying commensal bacteria</article-title><source>Science</source><year>2004</year><volume>303</volume><fpage>1662</fpage><lpage>1665</lpage><pub-id pub-id-type="doi">10.1126/science.1091334</pub-id><pub-id pub-id-type="pmid">15016999</pub-id></element-citation></ref><ref id="B35-vaccines-09-00162"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mathias</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pais</surname><given-names>B.</given-names></name><name name-style="western"><surname>Favre</surname><given-names>L.</given-names></name><name name-style="western"><surname>Benyacoub</surname><given-names>J.</given-names></name><name name-style="western"><surname>Corthesy</surname><given-names>B.</given-names></name></person-group><article-title>Role of secretory IgA in the mucosal sensing of commensal bacteria</article-title><source>Gut Microbes</source><year>2014</year><volume>5</volume><fpage>688</fpage><lpage>695</lpage><pub-id pub-id-type="doi">10.4161/19490976.2014.983763</pub-id><pub-id pub-id-type="pmid">25536286</pub-id><pub-id pub-id-type="pmcid">PMC4615909</pub-id></element-citation></ref><ref id="B36-vaccines-09-00162"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rol</surname><given-names>N.</given-names></name><name name-style="western"><surname>Favre</surname><given-names>L.</given-names></name><name name-style="western"><surname>Benyacoub</surname><given-names>J.</given-names></name><name name-style="western"><surname>Corthesy</surname><given-names>B.</given-names></name></person-group><article-title>The role of secretory immunoglobulin A in the natural sensing of commensal bacteria by mouse Peyer&#8217;s patch dendritic cells</article-title><source>J. Biol. Chem.</source><year>2012</year><volume>287</volume><fpage>40074</fpage><lpage>40082</lpage><pub-id pub-id-type="doi">10.1074/jbc.M112.405001</pub-id><pub-id pub-id-type="pmid">23027876</pub-id><pub-id pub-id-type="pmcid">PMC3501041</pub-id></element-citation></ref><ref id="B37-vaccines-09-00162"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Flannigan</surname><given-names>K.L.</given-names></name><name name-style="western"><surname>Geem</surname><given-names>D.</given-names></name><name name-style="western"><surname>Harusato</surname><given-names>A.</given-names></name><name name-style="western"><surname>Denning</surname><given-names>T.L.</given-names></name></person-group><article-title>Intestinal Antigen-Presenting Cells: Key Regulators of Immune Homeostasis and Inflammation</article-title><source>Am. J. Pathol.</source><year>2015</year><volume>185</volume><fpage>1809</fpage><lpage>1819</lpage><pub-id pub-id-type="doi">10.1016/j.ajpath.2015.02.024</pub-id><pub-id pub-id-type="pmid">25976247</pub-id><pub-id pub-id-type="pmcid">PMC4483458</pub-id></element-citation></ref><ref id="B38-vaccines-09-00162"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Worbs</surname><given-names>T.</given-names></name><name name-style="western"><surname>Hammerschmidt</surname><given-names>S.I.</given-names></name><name name-style="western"><surname>Forster</surname><given-names>R.</given-names></name></person-group><article-title>Dendritic cell migration in health and disease</article-title><source>Nat. Rev. Immunol.</source><year>2017</year><volume>17</volume><fpage>30</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.1038/nri.2016.116</pub-id><pub-id pub-id-type="pmid">27890914</pub-id></element-citation></ref><ref id="B39-vaccines-09-00162"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cheng</surname><given-names>H.Y.</given-names></name><name name-style="western"><surname>Ning</surname><given-names>M.X.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>D.K.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>W.T.</given-names></name></person-group><article-title>Interactions between the Gut Microbiota and the Host Innate Immune Response Against Pathogens</article-title><source>Front. Immunol.</source><year>2019</year><volume>10</volume><fpage>607</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2019.00607</pub-id><pub-id pub-id-type="pmid">30984184</pub-id><pub-id pub-id-type="pmcid">PMC6449424</pub-id></element-citation></ref><ref id="B40-vaccines-09-00162"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Caballero</surname><given-names>S.</given-names></name><name name-style="western"><surname>Pamer</surname><given-names>E.G.</given-names></name></person-group><article-title>Microbiota-mediated inflammation and antimicrobial defense in the intestine</article-title><source>Annu. Rev. Immunol.</source><year>2015</year><volume>33</volume><fpage>227</fpage><lpage>256</lpage><pub-id pub-id-type="doi">10.1146/annurev-immunol-032713-120238</pub-id><pub-id pub-id-type="pmid">25581310</pub-id><pub-id pub-id-type="pmcid">PMC4540477</pub-id></element-citation></ref><ref id="B41-vaccines-09-00162"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gewirtz</surname><given-names>A.T.</given-names></name><name name-style="western"><surname>Navas</surname><given-names>T.A.</given-names></name><name name-style="western"><surname>Lyons</surname><given-names>S.</given-names></name><name name-style="western"><surname>Godowski</surname><given-names>P.J.</given-names></name><name name-style="western"><surname>Madara</surname><given-names>J.L.</given-names></name></person-group><article-title>Cutting edge: Bacterial flagellin activates basolaterally expressed TLR5 to induce epithelial proinflammatory gene expression</article-title><source>J. Immunol.</source><year>2001</year><volume>167</volume><fpage>1882</fpage><lpage>1885</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.167.4.1882</pub-id><pub-id pub-id-type="pmid">11489966</pub-id></element-citation></ref><ref id="B42-vaccines-09-00162"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>F.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>A.T.</given-names></name><name name-style="western"><surname>Xue</surname><given-names>X.</given-names></name><name name-style="western"><surname>Yao</surname><given-names>S.</given-names></name><name name-style="western"><surname>Evans-Marin</surname><given-names>H.L.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.-Q.</given-names></name><name name-style="western"><surname>Cong </surname><given-names>Y.</given-names></name></person-group><article-title>TLR5 mediates CD172alpha(+) intestinal lamina propria dendritic cell induction of Th17 cells</article-title><source>Sci. Rep.</source><year>2016</year><volume>6</volume><fpage>22040</fpage><pub-id pub-id-type="doi">10.1038/srep22040</pub-id><pub-id pub-id-type="pmid">26907705</pub-id><pub-id pub-id-type="pmcid">PMC4764953</pub-id></element-citation></ref><ref id="B43-vaccines-09-00162"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cullender</surname><given-names>T.C.</given-names></name><name name-style="western"><surname>Chassaing</surname><given-names>B.</given-names></name><name name-style="western"><surname>Janzon</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>K.</given-names></name><name name-style="western"><surname>Muller</surname><given-names>C.E.</given-names></name><name name-style="western"><surname>Werner</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Angenent</surname><given-names>L.T.</given-names></name><name name-style="western"><surname>Bell</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Hay</surname><given-names>A.G.</given-names></name><name name-style="western"><surname>Peterson</surname><given-names>D.A.</given-names></name><etal/></person-group><article-title>Innate and adaptive immunity interact to quench microbiome flagellar motility in the gut</article-title><source>Cell Host Microbe</source><year>2013</year><volume>14</volume><fpage>571</fpage><lpage>581</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2013.10.009</pub-id><pub-id pub-id-type="pmid">24237702</pub-id><pub-id pub-id-type="pmcid">PMC3920589</pub-id></element-citation></ref><ref id="B44-vaccines-09-00162"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Killig</surname><given-names>M.</given-names></name><name name-style="western"><surname>Glatzer</surname><given-names>T.</given-names></name><name name-style="western"><surname>Romagnani</surname><given-names>C.</given-names></name></person-group><article-title>Recognition strategies of group 3 innate lymphoid cells</article-title><source>Front. Immunol.</source><year>2014</year><volume>5</volume><fpage>142</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2014.00142</pub-id><pub-id pub-id-type="pmid">24744763</pub-id><pub-id pub-id-type="pmcid">PMC3978353</pub-id></element-citation></ref><ref id="B45-vaccines-09-00162"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Satoh-Takayama</surname><given-names>N.</given-names></name></person-group><article-title>Heterogeneity and diversity of group 3 innate lymphoid cells: New cells on the block</article-title><source>Int. Immunol.</source><year>2016</year><volume>28</volume><fpage>29</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1093/intimm/dxv054</pub-id><pub-id pub-id-type="pmid">26462712</pub-id></element-citation></ref><ref id="B46-vaccines-09-00162"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sawa</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lochner</surname><given-names>M.</given-names></name><name name-style="western"><surname>Satoh-Takayama</surname><given-names>N.</given-names></name><name name-style="western"><surname>Dulauroy</surname><given-names>S.</given-names></name><name name-style="western"><surname>Berard</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kleinschek</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cua</surname><given-names>D.</given-names></name><name name-style="western"><surname>Di Santo</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Eberl</surname><given-names>G.</given-names></name></person-group><article-title>RORgammat+ innate lymphoid cells regulate intestinal homeostasis by integrating negative signals from the symbiotic microbiota</article-title><source>Nat. Immunol.</source><year>2011</year><volume>12</volume><fpage>320</fpage><lpage>326</lpage><pub-id pub-id-type="doi">10.1038/ni.2002</pub-id><pub-id pub-id-type="pmid">21336274</pub-id></element-citation></ref><ref id="B47-vaccines-09-00162"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Blander</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Sander</surname><given-names>L.E.</given-names></name></person-group><article-title>Beyond pattern recognition: Five immune checkpoints for scaling the microbial threat</article-title><source>Nat. Rev. Immunol.</source><year>2012</year><volume>12</volume><fpage>215</fpage><lpage>225</lpage><pub-id pub-id-type="doi">10.1038/nri3167</pub-id><pub-id pub-id-type="pmid">22362354</pub-id></element-citation></ref><ref id="B48-vaccines-09-00162"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sander</surname><given-names>L.E.</given-names></name></person-group><article-title>Improved vaccines through targeted manipulation of the body&#8217;s immunological risk-assessment?</article-title><source>Bioessays</source><year>2012</year><volume>34</volume><fpage>876</fpage><lpage>884</lpage><pub-id pub-id-type="doi">10.1002/bies.201200057</pub-id><pub-id pub-id-type="pmid">22815215</pub-id></element-citation></ref><ref id="B49-vaccines-09-00162"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kasturi</surname><given-names>S.P.</given-names></name><name name-style="western"><surname>Skountzou</surname><given-names>I.</given-names></name><name name-style="western"><surname>Albrecht</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Koutsonanos</surname><given-names>D.</given-names></name><name name-style="western"><surname>Hua</surname><given-names>T.</given-names></name><name name-style="western"><surname>Nakaya</surname><given-names>H.I.</given-names></name><name name-style="western"><surname>Ravindran</surname><given-names>R.</given-names></name><name name-style="western"><surname>Stewart</surname><given-names>S.</given-names></name><name name-style="western"><surname>Alam</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kwissa</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Programming the magnitude and persistence of antibody responses with innate immunity</article-title><source>Nature</source><year>2011</year><volume>470</volume><fpage>543</fpage><lpage>547</lpage><pub-id pub-id-type="doi">10.1038/nature09737</pub-id><pub-id pub-id-type="pmid">21350488</pub-id><pub-id pub-id-type="pmcid">PMC3057367</pub-id></element-citation></ref><ref id="B50-vaccines-09-00162"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gause</surname><given-names>K.T.</given-names></name><name name-style="western"><surname>Wheatley</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Cui</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kent</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Caruso</surname><given-names>F.</given-names></name></person-group><article-title>Immunological Principles Guiding the Rational Design of Particles for Vaccine Delivery</article-title><source>ACS Nano</source><year>2017</year><volume>11</volume><fpage>54</fpage><lpage>68</lpage><pub-id pub-id-type="doi">10.1021/acsnano.6b07343</pub-id><pub-id pub-id-type="pmid">28075558</pub-id></element-citation></ref><ref id="B51-vaccines-09-00162"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kanekiyo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Joyce</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>Meng</surname><given-names>G.</given-names></name><name name-style="western"><surname>Whittle</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Baxa</surname><given-names>U.</given-names></name><name name-style="western"><surname>Yamamoto</surname><given-names>T.</given-names></name><name name-style="western"><surname>Narpala</surname><given-names>S.</given-names></name><name name-style="western"><surname>Todd</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Rao</surname><given-names>S.S.</given-names></name><etal/></person-group><article-title>Rational Design of an Epstein-Barr Virus Vaccine Targeting the Receptor-Binding Site</article-title><source>Cell</source><year>2015</year><volume>162</volume><fpage>1090</fpage><lpage>1100</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2015.07.043</pub-id><pub-id pub-id-type="pmid">26279189</pub-id><pub-id pub-id-type="pmcid">PMC4757492</pub-id></element-citation></ref><ref id="B52-vaccines-09-00162"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Micoli</surname><given-names>F.</given-names></name><name name-style="western"><surname>Rondini</surname><given-names>S.</given-names></name><name name-style="western"><surname>Alfini</surname><given-names>R.</given-names></name><name name-style="western"><surname>Lanzilao</surname><given-names>L.</given-names></name><name name-style="western"><surname>Necchi</surname><given-names>F.</given-names></name><name name-style="western"><surname>Negrea</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rossi</surname><given-names>O.</given-names></name><name name-style="western"><surname>Brandt</surname><given-names>C.</given-names></name><name name-style="western"><surname>Clare</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mastroeni</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Comparative immunogenicity and efficacy of equivalent outer membrane vesicle and glycoconjugate vaccines against nontyphoidal <italic toggle="yes">Salmonella</italic></article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2018</year><volume>115</volume><fpage>10428</fpage><lpage>10433</lpage><pub-id pub-id-type="doi">10.1073/pnas.1807655115</pub-id><pub-id pub-id-type="pmid">30262653</pub-id><pub-id pub-id-type="pmcid">PMC6187145</pub-id></element-citation></ref><ref id="B53-vaccines-09-00162"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sander</surname><given-names>L.E.</given-names></name><name name-style="western"><surname>Davis</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Boekschoten</surname><given-names>M.V.</given-names></name><name name-style="western"><surname>Amsen</surname><given-names>D.</given-names></name><name name-style="western"><surname>Dascher</surname><given-names>C.C.</given-names></name><name name-style="western"><surname>Ryffel</surname><given-names>B.</given-names></name><name name-style="western"><surname>Swanson</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Muller</surname><given-names>M.</given-names></name><name name-style="western"><surname>Blander</surname><given-names>J.M.</given-names></name></person-group><article-title>Detection of prokaryotic mRNA signifies microbial viability and promotes immunity</article-title><source>Nature</source><year>2011</year><volume>474</volume><fpage>385</fpage><lpage>389</lpage><pub-id pub-id-type="doi">10.1038/nature10072</pub-id><pub-id pub-id-type="pmid">21602824</pub-id><pub-id pub-id-type="pmcid">PMC3289942</pub-id></element-citation></ref><ref id="B54-vaccines-09-00162"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ugolini</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sander</surname><given-names>L.E.</given-names></name></person-group><article-title>Dead or alive: How the immune system detects microbial viability</article-title><source>Curr. Opin. Immunol.</source><year>2019</year><volume>56</volume><fpage>60</fpage><lpage>66</lpage><pub-id pub-id-type="doi">10.1016/j.coi.2018.09.018</pub-id><pub-id pub-id-type="pmid">30366275</pub-id></element-citation></ref><ref id="B55-vaccines-09-00162"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kitamoto</surname><given-names>S.</given-names></name><name name-style="western"><surname>Nagao-Kitamoto</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kuffa</surname><given-names>P.</given-names></name><name name-style="western"><surname>Kamada</surname><given-names>N.</given-names></name></person-group><article-title>Regulation of virulence: The rise and fall of gastrointestinal pathogens</article-title><source>J. Gastroenterol.</source><year>2016</year><volume>51</volume><fpage>195</fpage><lpage>205</lpage><pub-id pub-id-type="doi">10.1007/s00535-015-1141-5</pub-id><pub-id pub-id-type="pmid">26553054</pub-id><pub-id pub-id-type="pmcid">PMC4767578</pub-id></element-citation></ref><ref id="B56-vaccines-09-00162"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Azimi</surname><given-names>T.</given-names></name><name name-style="western"><surname>Zamirnasta</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sani</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Soltan Dallal</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Nasser</surname><given-names>A.</given-names></name></person-group><article-title>Molecular Mechanisms of <italic toggle="yes">Salmonella</italic> Effector Proteins: A Comprehensive Review</article-title><source>Infect. Drug Resist.</source><year>2020</year><volume>13</volume><fpage>11</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.2147/IDR.S230604</pub-id><pub-id pub-id-type="pmid">32021316</pub-id><pub-id pub-id-type="pmcid">PMC6954085</pub-id></element-citation></ref><ref id="B57-vaccines-09-00162"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Giogha</surname><given-names>C.</given-names></name><name name-style="western"><surname>Hartland</surname><given-names>E.L.</given-names></name></person-group><article-title>Molecular mechanisms employed by enteric bacterial pathogens to antagonise host innate immunity</article-title><source>Curr. Opin. Microbiol.</source><year>2020</year><volume>59</volume><fpage>58</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.1016/j.mib.2020.07.015</pub-id><pub-id pub-id-type="pmid">32862049</pub-id></element-citation></ref><ref id="B58-vaccines-09-00162"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rogers</surname><given-names>A.W.L.</given-names></name><name name-style="western"><surname>Tsolis</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>B&#228;umler</surname><given-names>A.J.</given-names></name></person-group><article-title><italic toggle="yes">Salmonella</italic> versus the Microbiome</article-title><source>Microbiol. Mol. Biol. Rev.</source><year>2021</year><volume>85</volume><fpage>e00027-19</fpage><pub-id pub-id-type="doi">10.1128/MMBR.00027-19</pub-id><pub-id pub-id-type="pmid">33361269</pub-id><pub-id pub-id-type="pmcid">PMC8549850</pub-id></element-citation></ref><ref id="B59-vaccines-09-00162"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Odendall</surname><given-names>C.</given-names></name><name name-style="western"><surname>Kagan</surname><given-names>J.C.</given-names></name></person-group><article-title>Activation and pathogenic manipulation of the sensors of the innate immune system</article-title><source>Microbes Infect. Inst. Pasteur</source><year>2017</year><volume>19</volume><fpage>229</fpage><lpage>237</lpage><pub-id pub-id-type="doi">10.1016/j.micinf.2017.01.003</pub-id><pub-id pub-id-type="pmcid">PMC6697111</pub-id><pub-id pub-id-type="pmid">28093320</pub-id></element-citation></ref><ref id="B60-vaccines-09-00162"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kagan</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Medzhitov</surname><given-names>R.</given-names></name></person-group><article-title>Phosphoinositide-mediated adaptor recruitment controls Toll-like receptor signaling</article-title><source>Cell</source><year>2006</year><volume>125</volume><fpage>943</fpage><lpage>955</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2006.03.047</pub-id><pub-id pub-id-type="pmid">16751103</pub-id></element-citation></ref><ref id="B61-vaccines-09-00162"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>G.</given-names></name><name name-style="western"><surname>Svenungsson</surname><given-names>B.</given-names></name><name name-style="western"><surname>K&#228;rnell</surname><given-names>A.</given-names></name><name name-style="western"><surname>Weintraub</surname><given-names>A.</given-names></name></person-group><article-title>Prevalence of enterotoxigenic <italic toggle="yes">Bacteroides fragilis</italic> in adult patients with diarrhea and healthy controls</article-title><source>Clin. Infect. Dis.</source><year>1999</year><volume>29</volume><fpage>590</fpage><lpage>594</lpage><pub-id pub-id-type="doi">10.1086/598639</pub-id><pub-id pub-id-type="pmid">10530453</pub-id></element-citation></ref><ref id="B62-vaccines-09-00162"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Pu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bai</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>D.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>G.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>X.</given-names></name><etal/></person-group><article-title>Species-Level Analysis of Human Gut Microbiota With Metataxonomics</article-title><source>Front. Microbiol.</source><year>2020</year><volume>11</volume><fpage>2029</fpage><pub-id pub-id-type="doi">10.3389/fmicb.2020.02029</pub-id><pub-id pub-id-type="pmid">32983030</pub-id><pub-id pub-id-type="pmcid">PMC7479098</pub-id></element-citation></ref><ref id="B63-vaccines-09-00162"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hecht</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Casterline</surname><given-names>B.W.</given-names></name><name name-style="western"><surname>Choi</surname><given-names>V.M.</given-names></name><name name-style="western"><surname>Bubeck Wardenburg</surname><given-names>J.</given-names></name></person-group><article-title>A Two-Component System Regulates <italic toggle="yes">Bacteroides fragilis</italic> Toxin to Maintain Intestinal Homeostasis and Prevent Lethal Disease</article-title><source>Cell Host Microbe</source><year>2017</year><volume>22</volume><fpage>443</fpage><lpage>448.e5</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2017.08.007</pub-id><pub-id pub-id-type="pmid">28943327</pub-id><pub-id pub-id-type="pmcid">PMC5839110</pub-id></element-citation></ref><ref id="B64-vaccines-09-00162"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Galen</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Gomez-Duarte</surname><given-names>O.G.</given-names></name><name name-style="western"><surname>Losonsky</surname><given-names>G.</given-names></name><name name-style="western"><surname>Halpern</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Lauderbaugh</surname><given-names>C.S.</given-names></name><name name-style="western"><surname>Kaintuck</surname><given-names>S.</given-names></name><name name-style="western"><surname>Reymann</surname><given-names>M.K.</given-names></name><name name-style="western"><surname>Levine</surname><given-names>M.M.</given-names></name></person-group><article-title>A murine model of intranasal immunization to assess the immunogenicity of attenuated <italic toggle="yes">Salmonella typhi</italic> live vector vaccines in stimulating serum antibody responses to expressed foreign antigens</article-title><source>Vaccine</source><year>1997</year><volume>15</volume><fpage>700</fpage><lpage>708</lpage><pub-id pub-id-type="doi">10.1016/S0264-410X(96)00227-7</pub-id><pub-id pub-id-type="pmid">9178472</pub-id></element-citation></ref><ref id="B65-vaccines-09-00162"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pasetti</surname><given-names>M.F.</given-names></name><name name-style="western"><surname>Pickett</surname><given-names>T.E.</given-names></name><name name-style="western"><surname>Levine</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Sztein</surname><given-names>M.B.</given-names></name></person-group><article-title>A comparison of immunogenicity and in vivo distribution of <italic toggle="yes">Salmonella enterica</italic> serovar Typhi and Typhimurium live vector vaccines delivered by mucosal routes in the murine model</article-title><source>Vaccine</source><year>2000</year><volume>18</volume><fpage>3208</fpage><lpage>3213</lpage><pub-id pub-id-type="doi">10.1016/S0264-410X(00)00142-0</pub-id><pub-id pub-id-type="pmid">10869765</pub-id></element-citation></ref><ref id="B66-vaccines-09-00162"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pickett</surname><given-names>T.E.</given-names></name><name name-style="western"><surname>Pasetti</surname><given-names>M.F.</given-names></name><name name-style="western"><surname>Galen</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Sztein</surname><given-names>M.B.</given-names></name><name name-style="western"><surname>Levine</surname><given-names>M.M.</given-names></name></person-group><article-title>In vivo characterization of the murine intranasal model for assessing the immunogenicity of attenuated <italic toggle="yes">Salmonella enterica</italic> serovar Typhi strains as live mucosal vaccines and as live vectors</article-title><source>Infect. Immun.</source><year>2000</year><volume>68</volume><fpage>205</fpage><lpage>213</lpage><pub-id pub-id-type="doi">10.1128/IAI.68.1.205-213.2000</pub-id><pub-id pub-id-type="pmid">10603389</pub-id><pub-id pub-id-type="pmcid">PMC97122</pub-id></element-citation></ref><ref id="B67-vaccines-09-00162"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tacket</surname><given-names>C.O.</given-names></name><name name-style="western"><surname>Sztein</surname><given-names>M.</given-names></name><name name-style="western"><surname>Losonsky</surname><given-names>G.</given-names></name><name name-style="western"><surname>Wasserman</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Nataro</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Edelman</surname><given-names>R.</given-names></name><name name-style="western"><surname>Pickard</surname><given-names>D.</given-names></name><name name-style="western"><surname>Dougan</surname><given-names>G.</given-names></name><name name-style="western"><surname>Chatfield</surname><given-names>S.</given-names></name><name name-style="western"><surname>Levine</surname><given-names>M.M.</given-names></name><etal/></person-group><article-title>Safety of live oral <italic toggle="yes">Salmonella typhi</italic> vaccine strains with deletions in <italic toggle="yes">htrA</italic> and <italic toggle="yes">aroC aroD</italic> and immune responses in humans</article-title><source>Infect. Immun.</source><year>1997</year><volume>65</volume><fpage>452</fpage><lpage>456</lpage><pub-id pub-id-type="doi">10.1128/IAI.65.2.452-456.1997</pub-id><pub-id pub-id-type="pmid">9009296</pub-id><pub-id pub-id-type="pmcid">PMC174616</pub-id></element-citation></ref><ref id="B68-vaccines-09-00162"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tacket</surname><given-names>C.O.</given-names></name><name name-style="western"><surname>Sztein</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wasserman</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Losonsky</surname><given-names>G.</given-names></name><name name-style="western"><surname>Kotloff</surname><given-names>K.</given-names></name><name name-style="western"><surname>Wyant</surname><given-names>T.L.</given-names></name><name name-style="western"><surname>Nataro</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Edelman</surname><given-names>R.</given-names></name><name name-style="western"><surname>Perry</surname><given-names>J.G.</given-names></name><name name-style="western"><surname>Bedford</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Phase 2 clinical trial of attenuated <italic toggle="yes">Salmonella enterica</italic> serovar Typhi oral live vector vaccine CVD 908-<italic toggle="yes">htrA</italic> in U.S. volunteers</article-title><source>Infect. Immun.</source><year>2000</year><volume>68</volume><fpage>1196</fpage><lpage>1201</lpage><pub-id pub-id-type="doi">10.1128/IAI.68.3.1196-1201.2000</pub-id><pub-id pub-id-type="pmid">10678926</pub-id><pub-id pub-id-type="pmcid">PMC97267</pub-id></element-citation></ref><ref id="B69-vaccines-09-00162"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tacket</surname><given-names>C.O.</given-names></name><name name-style="western"><surname>Hone</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Losonsky</surname><given-names>G.A.</given-names></name><name name-style="western"><surname>Guers</surname><given-names>L.</given-names></name><name name-style="western"><surname>Edelman</surname><given-names>R.</given-names></name><name name-style="western"><surname>Levine</surname><given-names>M.M.</given-names></name></person-group><article-title>Clinical acceptability and immunogenicity of CVD 908 <italic toggle="yes">Salmonella typhi</italic> vaccine strain</article-title><source>Vaccine</source><year>1992</year><volume>10</volume><fpage>443</fpage><lpage>446</lpage><pub-id pub-id-type="doi">10.1016/0264-410X(92)90392-W</pub-id><pub-id pub-id-type="pmid">1609547</pub-id></element-citation></ref><ref id="B70-vaccines-09-00162"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tacket</surname><given-names>C.O.</given-names></name><name name-style="western"><surname>Hone</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Curtiss Iii</surname><given-names>R.</given-names></name><name name-style="western"><surname>Kelly</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Losonsky</surname><given-names>G.</given-names></name><name name-style="western"><surname>Guers</surname><given-names>L.</given-names></name><name name-style="western"><surname>Harris</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Edelman</surname><given-names>R.</given-names></name><name name-style="western"><surname>Levine</surname><given-names>M.M.</given-names></name></person-group><article-title>Comparison of the safety and immunogenicity of &#916;<italic toggle="yes">aroC</italic> &#916;<italic toggle="yes">aroD</italic> and &#916;<italic toggle="yes">cya</italic> &#916;<italic toggle="yes">crp Salmonella typhi</italic> strains in adult volunteers</article-title><source>Infect. Immun.</source><year>1992</year><volume>60</volume><fpage>536</fpage><lpage>541</lpage><pub-id pub-id-type="doi">10.1128/IAI.60.2.536-541.1992</pub-id><pub-id pub-id-type="pmid">1730487</pub-id><pub-id pub-id-type="pmcid">PMC257661</pub-id></element-citation></ref><ref id="B71-vaccines-09-00162"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Galen</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Curtiss</surname><given-names>R.</given-names><suffix>3rd</suffix></name></person-group><article-title>The delicate balance in genetically engineering live vaccines</article-title><source>Vaccine.</source><year>2014</year><volume>32</volume><fpage>4376</fpage><lpage>4385</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2013.12.026</pub-id><pub-id pub-id-type="pmid">24370705</pub-id><pub-id pub-id-type="pmcid">PMC4069233</pub-id></element-citation></ref><ref id="B72-vaccines-09-00162"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Germanier</surname><given-names>R.</given-names></name><name name-style="western"><surname>Fuer</surname><given-names>E.</given-names></name></person-group><article-title>Isolation and characterization of <italic toggle="yes">galE</italic> mutant Ty 21a of <italic toggle="yes">Salmonella typhi</italic>: A candidate strain for a live, oral typhoid vaccine</article-title><source>J. Infect. Dis.</source><year>1975</year><volume>131</volume><fpage>553</fpage><lpage>558</lpage><pub-id pub-id-type="doi">10.1093/infdis/131.5.553</pub-id><pub-id pub-id-type="pmid">1092768</pub-id></element-citation></ref><ref id="B73-vaccines-09-00162"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kopecko</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Sieber</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ures</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Furer</surname><given-names>A.</given-names></name><name name-style="western"><surname>Schlup</surname><given-names>J.</given-names></name><name name-style="western"><surname>Knof</surname><given-names>U.</given-names></name><name name-style="western"><surname>Collioud</surname><given-names>A.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>D.</given-names></name><name name-style="western"><surname>Colburn</surname><given-names>K.</given-names></name><name name-style="western"><surname>Dietrich</surname><given-names>G.</given-names></name></person-group><article-title>Genetic stability of vaccine strain <italic toggle="yes">Salmonella</italic> Typhi Ty21a over 25 years</article-title><source>Int. J. Med. Microbiol.</source><year>2009</year><volume>299</volume><fpage>233</fpage><lpage>246</lpage><pub-id pub-id-type="doi">10.1016/j.ijmm.2008.09.003</pub-id><pub-id pub-id-type="pmid">19121604</pub-id></element-citation></ref><ref id="B74-vaccines-09-00162"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Galen</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Levine</surname><given-names>M.M.</given-names></name></person-group><article-title>Can a &#8216;flawless&#8217; live vector vaccine strain be engineered?</article-title><source>Trends Microbiol.</source><year>2001</year><volume>9</volume><fpage>372</fpage><lpage>376</lpage><pub-id pub-id-type="doi">10.1016/S0966-842X(01)02096-0</pub-id><pub-id pub-id-type="pmid">11514219</pub-id></element-citation></ref><ref id="B75-vaccines-09-00162"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Galen</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Pasetti</surname><given-names>M.F.</given-names></name><name name-style="western"><surname>Tennant</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ruiz-Olvera</surname><given-names>P.</given-names></name><name name-style="western"><surname>Sztein</surname><given-names>M.B.</given-names></name><name name-style="western"><surname>Levine</surname><given-names>M.M.</given-names></name></person-group><article-title>Salmonella enterica serovar Typhi live vector vaccines finally come of age</article-title><source>Immunol. Cell Biol.</source><year>2009</year><volume>87</volume><fpage>400</fpage><lpage>412</lpage><pub-id pub-id-type="doi">10.1038/icb.2009.31</pub-id><pub-id pub-id-type="pmid">19417771</pub-id><pub-id pub-id-type="pmcid">PMC3747779</pub-id></element-citation></ref><ref id="B76-vaccines-09-00162"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kong</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Curtiss</surname><given-names>R.</given-names><suffix>3rd</suffix></name></person-group><article-title>New technologies in developing recombinant attenuated Salmonella vaccine vectors</article-title><source>Microb. Pathog.</source><year>2013</year><volume>58</volume><fpage>17</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.1016/j.micpath.2012.10.006</pub-id><pub-id pub-id-type="pmid">23142647</pub-id><pub-id pub-id-type="pmcid">PMC3587120</pub-id></element-citation></ref><ref id="B77-vaccines-09-00162"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roland</surname><given-names>K.L.</given-names></name><name name-style="western"><surname>Brenneman</surname><given-names>K.E.</given-names></name></person-group><article-title>Salmonella as a vaccine delivery vehicle</article-title><source>Expert Rev. Vaccines</source><year>2013</year><volume>12</volume><fpage>1033</fpage><lpage>1045</lpage><pub-id pub-id-type="doi">10.1586/14760584.2013.825454</pub-id><pub-id pub-id-type="pmid">24053397</pub-id><pub-id pub-id-type="pmcid">PMC3956298</pub-id></element-citation></ref><ref id="B78-vaccines-09-00162"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Levine</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Tacket</surname><given-names>C.O.</given-names></name><name name-style="western"><surname>Sztein</surname><given-names>M.B.</given-names></name></person-group><article-title>Host-<italic toggle="yes">Salmonella</italic> interaction: Human trials</article-title><source>Microbes Infect.</source><year>2001</year><volume>3</volume><fpage>1271</fpage><lpage>1279</lpage><pub-id pub-id-type="doi">10.1016/S1286-4579(01)01487-3</pub-id><pub-id pub-id-type="pmid">11755415</pub-id></element-citation></ref><ref id="B79-vaccines-09-00162"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sztein</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tanner</surname><given-names>M.K.</given-names></name><name name-style="western"><surname>Polotsky</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Orenstein</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Levine</surname><given-names>M.M.</given-names></name></person-group><article-title>Cytotoxic T lymphocytes after oral immunization with attenuated vaccine strains of <italic toggle="yes">Salmonella typhi</italic> in humans</article-title><source>J. Immunol.</source><year>1995</year><volume>155</volume><fpage>3987</fpage><lpage>3993</lpage><pub-id pub-id-type="pmid">7561107</pub-id></element-citation></ref><ref id="B80-vaccines-09-00162"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sztein</surname><given-names>M.B.</given-names></name></person-group><article-title>Cell-mediated immunity and antibody responses elicited by attenuated Salmonella enterica Serovar Typhi strains used as live oral vaccines in humans</article-title><source>Clin Infect. Dis.</source><year>2007</year><volume>45</volume><fpage>S15</fpage><lpage>S19</lpage><pub-id pub-id-type="doi">10.1086/518140</pub-id><pub-id pub-id-type="pmid">17582562</pub-id></element-citation></ref><ref id="B81-vaccines-09-00162"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sztein</surname><given-names>M.B.</given-names></name><name name-style="western"><surname>Salerno-Goncalves</surname><given-names>R.</given-names></name><name name-style="western"><surname>McArthur</surname><given-names>M.A.</given-names></name></person-group><article-title>Complex adaptive immunity to enteric fevers in humans: Lessons learned and the path forward</article-title><source>Front. Immunol.</source><year>2014</year><volume>5</volume><fpage>516</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2014.00516</pub-id><pub-id pub-id-type="pmid">25386175</pub-id><pub-id pub-id-type="pmcid">PMC4209864</pub-id></element-citation></ref><ref id="B82-vaccines-09-00162"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brinkmann</surname><given-names>U.</given-names></name><name name-style="western"><surname>Mattes</surname><given-names>R.E.</given-names></name><name name-style="western"><surname>Buckel</surname><given-names>P.</given-names></name></person-group><article-title>High-level expression of recombinant genes in <italic toggle="yes">Escherichia coli</italic> is dependent on the availability of the <italic toggle="yes">dnaY</italic> gene product</article-title><source>Gene</source><year>1989</year><volume>85</volume><fpage>109</fpage><lpage>114</lpage><pub-id pub-id-type="doi">10.1016/0378-1119(89)90470-8</pub-id><pub-id pub-id-type="pmid">2515992</pub-id></element-citation></ref><ref id="B83-vaccines-09-00162"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zahn</surname><given-names>K.</given-names></name></person-group><article-title>Overexpression of an mRNA dependent on rare codons inhibits protein synthesis and cell growth</article-title><source>J. Bacteriol.</source><year>1996</year><volume>178</volume><fpage>2926</fpage><lpage>2933</lpage><pub-id pub-id-type="doi">10.1128/JB.178.10.2926-2933.1996</pub-id><pub-id pub-id-type="pmid">8631683</pub-id><pub-id pub-id-type="pmcid">PMC178030</pub-id></element-citation></ref><ref id="B84-vaccines-09-00162"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Glick</surname><given-names>B.R.</given-names></name></person-group><article-title>Metabolic load and heterologous gene expression</article-title><source>Biotechnol. Adv.</source><year>1995</year><volume>13</volume><fpage>247</fpage><lpage>261</lpage><pub-id pub-id-type="doi">10.1016/0734-9750(95)00004-A</pub-id><pub-id pub-id-type="pmid">14537822</pub-id></element-citation></ref><ref id="B85-vaccines-09-00162"><label>85.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Bailey</surname><given-names>J.E.</given-names></name></person-group><article-title>Host-vector interactions in <italic toggle="yes">Escherichia coli</italic></article-title><source>Advances in Biochemical Engineering Biotechnology</source><person-group person-group-type="editor"><name name-style="western"><surname>Fiechter</surname><given-names>A.</given-names></name></person-group><publisher-name>Springer</publisher-name><publisher-loc>Berlin, Germany</publisher-loc><year>1993</year><fpage>29</fpage><lpage>77</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/BFb0007195</pub-id><pub-id pub-id-type="pmid">8460576</pub-id></element-citation></ref><ref id="B86-vaccines-09-00162"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boe</surname><given-names>L.</given-names></name><name name-style="western"><surname>Gerdes</surname><given-names>K.</given-names></name><name name-style="western"><surname>Molin</surname><given-names>S.</given-names></name></person-group><article-title>Effects of genes exerting growth inhibition and plasmid stability on plasmid maintenance</article-title><source>J. Bacteriol.</source><year>1987</year><volume>169</volume><fpage>4646</fpage><lpage>4650</lpage><pub-id pub-id-type="doi">10.1128/JB.169.10.4646-4650.1987</pub-id><pub-id pub-id-type="pmid">3308847</pub-id><pub-id pub-id-type="pmcid">PMC213834</pub-id></element-citation></ref><ref id="B87-vaccines-09-00162"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Corchero</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Villaverde</surname><given-names>A.</given-names></name></person-group><article-title>Plasmid maintenance in <italic toggle="yes">Escherichia coli</italic> recombinant cultures is dramatically, steadily, and specifically influenced by features of the encoded proteins</article-title><source>Biotechnol. Bioeng.</source><year>1998</year><volume>58</volume><fpage>625</fpage><lpage>632</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/(SICI)1097-0290(19980620)58:6&amp;#x0003c;625::AID-BIT8&amp;#x0003e;3.0.CO;2-K</pub-id><pub-id pub-id-type="pmid">10099300</pub-id></element-citation></ref><ref id="B88-vaccines-09-00162"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Galen</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Nair</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.Y.</given-names></name><name name-style="western"><surname>Wasserman</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Tanner</surname><given-names>M.K.</given-names></name><name name-style="western"><surname>Sztein</surname><given-names>M.</given-names></name><name name-style="western"><surname>Levine</surname><given-names>M.M.</given-names></name></person-group><article-title>Optimization of plasmid maintenance in the attenuated live vector vaccine strain <italic toggle="yes">Salmonella typhi</italic> CVD 908-<italic toggle="yes">htrA</italic></article-title><source>Infect. Immun.</source><year>1999</year><volume>67</volume><fpage>6424</fpage><lpage>6433</lpage><pub-id pub-id-type="doi">10.1128/IAI.67.12.6424-6433.1999</pub-id><pub-id pub-id-type="pmid">10569759</pub-id><pub-id pub-id-type="pmcid">PMC97051</pub-id></element-citation></ref><ref id="B89-vaccines-09-00162"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roberts</surname><given-names>M.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bacon</surname><given-names>A.</given-names></name><name name-style="western"><surname>Chatfield</surname><given-names>S.</given-names></name></person-group><article-title>Oral vaccination against tetanus: Comparison of the immunogenicities of <italic toggle="yes">Salmonella</italic> strains expressing fragment C from the <italic toggle="yes">nirB</italic> and <italic toggle="yes">htrA</italic> promoters</article-title><source>Infect. Immun.</source><year>1998</year><volume>66</volume><fpage>3080</fpage><lpage>3087</lpage><pub-id pub-id-type="doi">10.1128/IAI.66.7.3080-3087.1998</pub-id><pub-id pub-id-type="pmid">9632569</pub-id><pub-id pub-id-type="pmcid">PMC108316</pub-id></element-citation></ref><ref id="B90-vaccines-09-00162"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Curtiss</surname><given-names>R.</given-names><suffix>III</suffix></name><name name-style="western"><surname>Galan</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Nakayama</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kelly</surname><given-names>S.M.</given-names></name></person-group><article-title>Stabilization of recombinant avirulent vaccine strains in vivo</article-title><source>Res. Microbiol.</source><year>1990</year><volume>141</volume><fpage>797</fpage><lpage>805</lpage><pub-id pub-id-type="doi">10.1016/0923-2508(90)90113-5</pub-id><pub-id pub-id-type="pmid">1966252</pub-id></element-citation></ref><ref id="B91-vaccines-09-00162"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tacket</surname><given-names>C.O.</given-names></name><name name-style="western"><surname>Kelley</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Schodel</surname><given-names>F.</given-names></name><name name-style="western"><surname>Losonsky</surname><given-names>G.</given-names></name><name name-style="western"><surname>Nataro</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Edelman</surname><given-names>R.</given-names></name><name name-style="western"><surname>Levine</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Curtiss III</surname><given-names>R.</given-names></name></person-group><article-title>Safety and immunogenicity in humans of an attenuated <italic toggle="yes">Salmonella typhi</italic> vaccine vector strain expressing plasmid-encoded hepatitis B antigens stabilized by the Asd-balanced lethal vector system</article-title><source>Infect. Immun.</source><year>1997</year><volume>65</volume><fpage>3381</fpage><lpage>3385</lpage><pub-id pub-id-type="doi">10.1128/IAI.65.8.3381-3385.1997</pub-id><pub-id pub-id-type="pmid">9234801</pub-id><pub-id pub-id-type="pmcid">PMC175478</pub-id></element-citation></ref><ref id="B92-vaccines-09-00162"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Su</surname><given-names>G.-F.</given-names></name><name name-style="western"><surname>Brahmbhatt</surname><given-names>H.N.</given-names></name><name name-style="western"><surname>de Lorenzo</surname><given-names>V.</given-names></name><name name-style="western"><surname>Wehland</surname><given-names>J.</given-names></name><name name-style="western"><surname>Timmis</surname><given-names>K.N.</given-names></name></person-group><article-title>Extracellular export of shiga toxin B-subunit/haemolysin A (C-terminus) fusion protein expressed in <italic toggle="yes">Salmonella typhimurium aroA</italic>- mutant and stimulation of B-subunit specific antibody responses in mice</article-title><source>Microb. Pathog.</source><year>1992</year><volume>13</volume><fpage>465</fpage><lpage>476</lpage><pub-id pub-id-type="doi">10.1016/0882-4010(92)90013-E</pub-id><pub-id pub-id-type="pmid">1302285</pub-id></element-citation></ref><ref id="B93-vaccines-09-00162"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hess</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gentschev</surname><given-names>I.</given-names></name><name name-style="western"><surname>Miko</surname><given-names>D.</given-names></name><name name-style="western"><surname>Welzel</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ladel</surname><given-names>C.</given-names></name><name name-style="western"><surname>Goebel</surname><given-names>W.</given-names></name><name name-style="western"><surname>Kaufmann</surname><given-names>S.H.E.</given-names></name></person-group><article-title>Superior efficacy of secreted over somatic antigen display in recombinant <italic toggle="yes">Salmonella</italic> vaccine induced protection against listeriosis</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>1996</year><volume>93</volume><fpage>1458</fpage><lpage>1463</lpage><pub-id pub-id-type="doi">10.1073/pnas.93.4.1458</pub-id><pub-id pub-id-type="pmid">8643654</pub-id><pub-id pub-id-type="pmcid">PMC1079202</pub-id></element-citation></ref><ref id="B94-vaccines-09-00162"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tzschaschel</surname><given-names>B.D.</given-names></name><name name-style="western"><surname>Guzman</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Timmis</surname><given-names>K.N.</given-names></name><name name-style="western"><surname>de Lorenzo</surname><given-names>V.</given-names></name></person-group><article-title>An <italic toggle="yes">Escherichia coli</italic> hemolysin transport system-based vector for the export of polypeptides: Export of Shiga-like toxin IIeB subunit by <italic toggle="yes">Salmonella typhimurium aroA</italic></article-title><source>Nat. Biotechnol.</source><year>1996</year><volume>14</volume><fpage>765</fpage><lpage>769</lpage><pub-id pub-id-type="doi">10.1038/nbt0696-765</pub-id><pub-id pub-id-type="pmid">9630987</pub-id></element-citation></ref><ref id="B95-vaccines-09-00162"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Russmann</surname><given-names>H.</given-names></name><name name-style="western"><surname>Shams</surname><given-names>H.</given-names></name><name name-style="western"><surname>Poblete</surname><given-names>F.</given-names></name><name name-style="western"><surname>Fu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Galan</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Donis</surname><given-names>R.O.</given-names></name></person-group><article-title>Delivery of epitopes by the <italic toggle="yes">Salmonella</italic> type III secretion system for vaccine development</article-title><source>Science</source><year>1998</year><volume>281</volume><fpage>565</fpage><lpage>568</lpage><pub-id pub-id-type="pmid">9677200</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.281.5376.565</pub-id></element-citation></ref><ref id="B96-vaccines-09-00162"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Russmann</surname><given-names>H.</given-names></name><name name-style="western"><surname>Igwe</surname><given-names>E.I.</given-names></name><name name-style="western"><surname>Sauer</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hardt</surname><given-names>W.D.</given-names></name><name name-style="western"><surname>Bubert</surname><given-names>A.</given-names></name><name name-style="western"><surname>Geginat</surname><given-names>G.</given-names></name></person-group><article-title>Protection against murine listeriosis by oral vaccination with recombinant <italic toggle="yes">Salmonella</italic> expressing hybrid <italic toggle="yes">Yersinia</italic> type III proteins</article-title><source>J. Immunol.</source><year>2001</year><volume>167</volume><fpage>357</fpage><lpage>365</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.167.1.357</pub-id><pub-id pub-id-type="pmid">11418671</pub-id></element-citation></ref><ref id="B97-vaccines-09-00162"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>J.-S.</given-names></name><name name-style="western"><surname>Shin</surname><given-names>K.-S.</given-names></name><name name-style="western"><surname>Pan</surname><given-names>J.-G.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>C.-J.</given-names></name></person-group><article-title>Surface-displayed viral antigens on <italic toggle="yes">Salmonella</italic> carrier vaccine</article-title><source>Nat. Biotechnol.</source><year>2000</year><volume>18</volume><fpage>645</fpage><lpage>648</lpage><pub-id pub-id-type="doi">10.1038/76494</pub-id><pub-id pub-id-type="pmid">10835603</pub-id></element-citation></ref><ref id="B98-vaccines-09-00162"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kang</surname><given-names>H.Y.</given-names></name><name name-style="western"><surname>Curtiss</surname><given-names>R.</given-names><suffix>III</suffix></name></person-group><article-title>Immune responses dependent on antigen location in recombinant attenuated <italic toggle="yes">Salmonella typhimurium</italic> vaccines following oral immunization</article-title><source>FEMS Immunol. Med. Microbiol.</source><year>2003</year><volume>37</volume><fpage>99</fpage><lpage>104</lpage><pub-id pub-id-type="doi">10.1016/S0928-8244(03)00063-4</pub-id><pub-id pub-id-type="pmid">12832112</pub-id></element-citation></ref><ref id="B99-vaccines-09-00162"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Galen</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>L.</given-names></name><name name-style="western"><surname>Chinchilla</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.Y.</given-names></name><name name-style="western"><surname>Pasetti</surname><given-names>M.F.</given-names></name><name name-style="western"><surname>Green</surname><given-names>J.</given-names></name><name name-style="western"><surname>Levine</surname><given-names>M.M.</given-names></name></person-group><article-title>Adaptation of the endogenous <italic toggle="yes">Salmonella enterica</italic> serovar Typhi <italic toggle="yes">clyA</italic>-encoded hemolysin for antigen export enhances the immunogenicity of anthrax protective antigen domain 4 expressed by the attenuated live-vector vaccine strain CVD 908-<italic toggle="yes">htrA</italic></article-title><source>Infect. Immun.</source><year>2004</year><volume>72</volume><fpage>7096</fpage><lpage>7106</lpage><pub-id pub-id-type="doi">10.1128/IAI.72.12.7096-7106.2004</pub-id><pub-id pub-id-type="pmid">15557633</pub-id><pub-id pub-id-type="pmcid">PMC529119</pub-id></element-citation></ref><ref id="B100-vaccines-09-00162"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Galen</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Chinchilla</surname><given-names>M.</given-names></name><name name-style="western"><surname>Pasetti</surname><given-names>M.F.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.Y.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>L.</given-names></name><name name-style="western"><surname>Rciniega-Martinez</surname><given-names>I.</given-names></name><name name-style="western"><surname>Silverman</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Levine</surname><given-names>M.M.</given-names></name></person-group><article-title>Mucosal immunization with attenuated <italic toggle="yes">Salmonella enterica</italic> serovar Typhi expressing protective antigen of anthrax toxin (PA83) primes monkeys for accelerated serum antibody responses to parenteral PA83 vaccine</article-title><source>J. Infect. Dis.</source><year>2009</year><volume>199</volume><fpage>326</fpage><lpage>335</lpage><pub-id pub-id-type="doi">10.1086/596066</pub-id><pub-id pub-id-type="pmid">19099487</pub-id><pub-id pub-id-type="pmcid">PMC2626152</pub-id></element-citation></ref><ref id="B101-vaccines-09-00162"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vindurampulle</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Attridge</surname><given-names>S.R.</given-names></name></person-group><article-title>Vector priming reduces the immunogenicity of <italic toggle="yes">Salmonella</italic>-based vaccines in Nramp1+/+ mice</article-title><source>Infect. Immun.</source><year>2003</year><volume>71</volume><fpage>2258</fpage><lpage>2261</lpage><pub-id pub-id-type="doi">10.1128/IAI.71.4.2258-2261.2003</pub-id><pub-id pub-id-type="pmid">12654852</pub-id><pub-id pub-id-type="pmcid">PMC152061</pub-id></element-citation></ref><ref id="B102-vaccines-09-00162"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vindurampulle</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Attridge</surname><given-names>S.R.</given-names></name></person-group><article-title>Impact of vector priming on the immunogenicity of recombinant <italic toggle="yes">Salmonella</italic> vaccines</article-title><source>Infect. Immun.</source><year>2003</year><volume>71</volume><fpage>287</fpage><lpage>297</lpage><pub-id pub-id-type="doi">10.1128/IAI.71.1.287-297.2003</pub-id><pub-id pub-id-type="pmid">12496178</pub-id><pub-id pub-id-type="pmcid">PMC143414</pub-id></element-citation></ref><ref id="B103-vaccines-09-00162"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Attridge</surname><given-names>S.R.</given-names></name><name name-style="western"><surname>Vindurampulle</surname><given-names>C.J.</given-names></name></person-group><article-title>Vector-primed mice display hypo-responsiveness to foreign antigen presented by recombinant <italic toggle="yes">Salmonella</italic> regardless of the route of delivery</article-title><source>Microb. Pathog.</source><year>2005</year><volume>39</volume><fpage>1</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1016/j.micpath.2005.05.004</pub-id><pub-id pub-id-type="pmid">16002258</pub-id></element-citation></ref><ref id="B104-vaccines-09-00162"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roberts</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bacon</surname><given-names>A.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chatfield</surname><given-names>S.</given-names></name></person-group><article-title>Prior immunity to homologous and heterologous <italic toggle="yes">Salmonella</italic> serotypes suppresses local and systemic anti-fragment C antibody responses and protection from tetanus toxin in mice immunized with <italic toggle="yes">Salmonella</italic> strains expressing fragment C</article-title><source>Infect. Immun.</source><year>1999</year><volume>67</volume><fpage>3810</fpage><lpage>3815</lpage><pub-id pub-id-type="doi">10.1128/IAI.67.8.3810-3815.1999</pub-id><pub-id pub-id-type="pmid">10417142</pub-id><pub-id pub-id-type="pmcid">PMC96658</pub-id></element-citation></ref><ref id="B105-vaccines-09-00162"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hill</surname><given-names>A.V.</given-names></name><name name-style="western"><surname>Reece</surname><given-names>W.</given-names></name><name name-style="western"><surname>Gothard</surname><given-names>P.</given-names></name><name name-style="western"><surname>Moorthy</surname><given-names>V.</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>M.</given-names></name><name name-style="western"><surname>Flanagan</surname><given-names>K.</given-names></name><name name-style="western"><surname>Plebanski</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hannan</surname><given-names>C.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>J.T.</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>R.</given-names></name><etal/></person-group><article-title>DNA-based vaccines for malaria: A heterologous prime-boost immunisation strategy</article-title><source>Dev. Biol. (Basel)</source><year>2000</year><volume>104</volume><fpage>171</fpage><lpage>179</lpage><pub-id pub-id-type="pmid">11713817</pub-id></element-citation></ref><ref id="B106-vaccines-09-00162"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ramshaw</surname><given-names>I.A.</given-names></name><name name-style="western"><surname>Ramsay</surname><given-names>A.J.</given-names></name></person-group><article-title>The prime-boost strategy: Exciting prospects for improved vaccination</article-title><source>Immunol. Today</source><year>2000</year><volume>21</volume><fpage>163</fpage><lpage>165</lpage><pub-id pub-id-type="doi">10.1016/S0167-5699(00)01612-1</pub-id><pub-id pub-id-type="pmid">10740236</pub-id></element-citation></ref><ref id="B107-vaccines-09-00162"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Londono-Arcila</surname><given-names>P.</given-names></name><name name-style="western"><surname>Freeman</surname><given-names>D.</given-names></name><name name-style="western"><surname>Kleanthous</surname><given-names>H.</given-names></name><name name-style="western"><surname>O&#8217;Dowd</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Lewis</surname><given-names>S.</given-names></name><name name-style="western"><surname>Turner</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Rees</surname><given-names>E.L.</given-names></name><name name-style="western"><surname>Tibbitts</surname><given-names>T.J.</given-names></name><name name-style="western"><surname>Greenwood</surname><given-names>J.</given-names></name><name name-style="western"><surname>Monath</surname><given-names>T.P.</given-names></name><etal/></person-group><article-title>Attenuated <italic toggle="yes">Salmonella enterica</italic> serovar Typhi expressing urease effectively immunizes mice against <italic toggle="yes">Helicobacter pylori</italic> challenge as part of a heterologous mucosal priming-parenteral boosting vaccination regimen</article-title><source>Infect. Immun.</source><year>2002</year><volume>70</volume><fpage>5096</fpage><lpage>5106</lpage><pub-id pub-id-type="doi">10.1128/IAI.70.9.5096-5106.2002</pub-id><pub-id pub-id-type="pmid">12183559</pub-id><pub-id pub-id-type="pmcid">PMC128259</pub-id></element-citation></ref><ref id="B108-vaccines-09-00162"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vindurampulle</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Cuberos</surname><given-names>L.F.</given-names></name><name name-style="western"><surname>Barry</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Pasetti</surname><given-names>M.F.</given-names></name><name name-style="western"><surname>Levine</surname><given-names>M.M.</given-names></name></person-group><article-title>Recombinant <italic toggle="yes">Salmonella enterica</italic> serovar Typhi in a prime-boost strategy</article-title><source>Vaccine</source><year>2004</year><volume>22</volume><fpage>3744</fpage><lpage>3750</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2004.03.025</pub-id><pub-id pub-id-type="pmid">15315855</pub-id></element-citation></ref><ref id="B109-vaccines-09-00162"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chinchilla</surname><given-names>M.</given-names></name><name name-style="western"><surname>Pasetti</surname><given-names>M.F.</given-names></name><name name-style="western"><surname>Medina-Moreno</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.Y.</given-names></name><name name-style="western"><surname>Gomez-Duarte</surname><given-names>O.G.</given-names></name><name name-style="western"><surname>Stout</surname><given-names>R.</given-names></name><name name-style="western"><surname>Levine</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Galen</surname><given-names>J.E.</given-names></name></person-group><article-title>Enhanced immunity to <italic toggle="yes">Plasmodium falciparum</italic> circumsporozoite protein (PfCSP) by using <italic toggle="yes">Salmonella enterica</italic> serovar Typhi expressing PfCSP and a PfCSP-encoding DNA vaccine in a heterologous prime-boost strategy</article-title><source>Infect. Immun.</source><year>2007</year><volume>75</volume><fpage>3769</fpage><lpage>3779</lpage><pub-id pub-id-type="doi">10.1128/IAI.00356-07</pub-id><pub-id pub-id-type="pmid">17502396</pub-id><pub-id pub-id-type="pmcid">PMC1951980</pub-id></element-citation></ref><ref id="B110-vaccines-09-00162"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Galen</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.Y.</given-names></name><name name-style="western"><surname>Carrasco</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Lloyd</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Mellado-Sanchez</surname><given-names>G.</given-names></name><name name-style="western"><surname>Diaz-McNair</surname><given-names>J.</given-names></name><name name-style="western"><surname>Franco</surname><given-names>O.</given-names></name><name name-style="western"><surname>Buskirk</surname><given-names>A.D.</given-names></name><name name-style="western"><surname>Nataro</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Pasetti</surname><given-names>M.F.</given-names></name></person-group><article-title>A Bivalent Typhoid Live Vector Vaccine Expressing both Chromosome- and Plasmid-Encoded <italic toggle="yes">Yersinia pestis</italic> Antigens Fully Protects against Murine Lethal Pulmonary Plague Infection</article-title><source>Infect. Immun.</source><year>2015</year><volume>83</volume><fpage>161</fpage><lpage>172</lpage><pub-id pub-id-type="doi">10.1128/IAI.02443-14</pub-id><pub-id pub-id-type="pmid">25332120</pub-id><pub-id pub-id-type="pmcid">PMC4288866</pub-id></element-citation></ref><ref id="B111-vaccines-09-00162"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boraschi</surname><given-names>D.</given-names></name><name name-style="western"><surname>Italiani</surname><given-names>P.</given-names></name></person-group><article-title>Immunosenescence and vaccine failure in the elderly: Strategies for improving response</article-title><source>Immunol. Lett.</source><year>2014</year><volume>162</volume><fpage>346</fpage><lpage>353</lpage><pub-id pub-id-type="doi">10.1016/j.imlet.2014.06.006</pub-id><pub-id pub-id-type="pmid">24960535</pub-id></element-citation></ref><ref id="B112-vaccines-09-00162"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhivaki</surname><given-names>D.</given-names></name><name name-style="western"><surname>Lo-Man</surname><given-names>R.</given-names></name></person-group><article-title>Unique aspects of the perinatal immune system</article-title><source>Nat. Rev. Immunol.</source><year>2017</year><volume>17</volume><fpage>495</fpage><lpage>507</lpage><pub-id pub-id-type="doi">10.1038/nri.2017.54</pub-id><pub-id pub-id-type="pmid">28627520</pub-id></element-citation></ref><ref id="B113-vaccines-09-00162"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stelekati</surname><given-names>E.</given-names></name><name name-style="western"><surname>Wherry</surname><given-names>E.J.</given-names></name></person-group><article-title>Chronic bystander infections and immunity to unrelated antigens</article-title><source>Cell Host Microbe</source><year>2012</year><volume>12</volume><fpage>458</fpage><lpage>469</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2012.10.001</pub-id><pub-id pub-id-type="pmid">23084915</pub-id><pub-id pub-id-type="pmcid">PMC3617576</pub-id></element-citation></ref><ref id="B114-vaccines-09-00162"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Uche</surname><given-names>I.V.</given-names></name><name name-style="western"><surname>MacLennan</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Saul</surname><given-names>A.</given-names></name></person-group><article-title>A Systematic Review of the Incidence, Risk Factors and Case Fatality Rates of Invasive Nontyphoidal Salmonella (iNTS) Disease in Africa (1966 to 2014)</article-title><source>PLoS Negl. Trop. Dis.</source><year>2017</year><volume>11</volume><elocation-id>e0005118</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pntd.0005118</pub-id><pub-id pub-id-type="pmid">28056035</pub-id><pub-id pub-id-type="pmcid">PMC5215826</pub-id></element-citation></ref><ref id="B115-vaccines-09-00162"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qadri</surname><given-names>F.</given-names></name><name name-style="western"><surname>Bhuiyan</surname><given-names>T.R.</given-names></name><name name-style="western"><surname>Sack</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Svennerholm</surname><given-names>A.M.</given-names></name></person-group><article-title>Immune responses and protection in children in developing countries induced by oral vaccines</article-title><source>Vaccine</source><year>2013</year><volume>31</volume><fpage>452</fpage><lpage>460</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2012.11.012</pub-id><pub-id pub-id-type="pmid">23153448</pub-id></element-citation></ref><ref id="B116-vaccines-09-00162"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Levine</surname><given-names>M.M.</given-names></name></person-group><article-title>Immunogenicity and efficacy of oral vaccines in developing countries: Lessons from a live cholera vaccine</article-title><source>BMC Biol.</source><year>2010</year><volume>8</volume><elocation-id>129</elocation-id><pub-id pub-id-type="doi">10.1186/1741-7007-8-129</pub-id><pub-id pub-id-type="pmid">20920375</pub-id><pub-id pub-id-type="pmcid">PMC2958895</pub-id></element-citation></ref><ref id="B117-vaccines-09-00162"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Prendergast</surname><given-names>A.J.</given-names></name></person-group><article-title>Malnutrition and vaccination in developing countries</article-title><source>Philos. Trans. R. Soc. B Biol. Sci.</source><year>2015</year><volume>370</volume><fpage>20140141</fpage><pub-id pub-id-type="doi">10.1098/rstb.2014.0141</pub-id><pub-id pub-id-type="pmid">25964453</pub-id><pub-id pub-id-type="pmcid">PMC4527386</pub-id></element-citation></ref><ref id="B118-vaccines-09-00162"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Donowitz</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Petri</surname><given-names>W.A.</given-names><suffix>Jr.</suffix></name></person-group><article-title>Pediatric small intestine bacterial overgrowth in low-income countries</article-title><source>Trends Mol Med.</source><year>2015</year><volume>21</volume><fpage>6</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1016/j.molmed.2014.11.001</pub-id><pub-id pub-id-type="pmid">25486880</pub-id><pub-id pub-id-type="pmcid">PMC4402728</pub-id></element-citation></ref><ref id="B119-vaccines-09-00162"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gilmartin</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Petri</surname><given-names>W.A.</given-names><suffix>Jr.</suffix></name></person-group><article-title>Exploring the role of environmental enteropathy in malnutrition, infant development and oral vaccine response</article-title><source>Philos. Trans. R. Soc. B Biol. Sci.</source><year>2015</year><volume>370</volume><fpage>20140143</fpage><pub-id pub-id-type="doi">10.1098/rstb.2014.0143</pub-id><pub-id pub-id-type="pmcid">PMC4527388</pub-id><pub-id pub-id-type="pmid">25964455</pub-id></element-citation></ref><ref id="B120-vaccines-09-00162"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Watanabe</surname><given-names>K.</given-names></name><name name-style="western"><surname>Petri</surname><given-names>W.A.</given-names><suffix>Jr.</suffix></name></person-group><article-title>Environmental Enteropathy: Elusive but Significant Subclinical Abnormalities in Developing Countries</article-title><source>EBioMedicine.</source><year>2016</year><volume>10</volume><fpage>25</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1016/j.ebiom.2016.07.030</pub-id><pub-id pub-id-type="pmid">27495791</pub-id><pub-id pub-id-type="pmcid">PMC5006727</pub-id></element-citation></ref><ref id="B121-vaccines-09-00162"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Suharyono</surname></name><name name-style="western"><surname>Simanjuntak</surname><given-names>C.</given-names></name><name name-style="western"><surname>Witham</surname><given-names>N.</given-names></name><name name-style="western"><surname>Punjabi</surname><given-names>N.</given-names></name><name name-style="western"><surname>Heppner</surname><given-names>D.G.</given-names></name><name name-style="western"><surname>Losonsky</surname><given-names>G.</given-names></name><name name-style="western"><surname>Totosudirjo</surname><given-names>H.</given-names></name><name name-style="western"><surname>Rifai</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Clemens</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lim</surname><given-names>Y.L.</given-names></name><etal/></person-group><article-title>Safety and immunogenicity of single-dose live oral cholera vaccine CVD 103-HgR in 5-9-year-old Indonesian children</article-title><source>Lancet</source><year>1992</year><volume>340</volume><fpage>689</fpage><lpage>694</lpage><pub-id pub-id-type="doi">10.1016/0140-6736(92)92231-4</pub-id><pub-id pub-id-type="pmid">1355798</pub-id></element-citation></ref><ref id="B122-vaccines-09-00162"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gotuzzo</surname><given-names>E.</given-names></name><name name-style="western"><surname>Butron</surname><given-names>B.</given-names></name><name name-style="western"><surname>Seas</surname><given-names>C.</given-names></name><name name-style="western"><surname>Penny</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ruiz</surname><given-names>R.</given-names></name><name name-style="western"><surname>Losonsky</surname><given-names>G.</given-names></name><name name-style="western"><surname>Lanata</surname><given-names>C.F.</given-names></name><name name-style="western"><surname>Wasserman</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Salazar</surname><given-names>E.</given-names></name><name name-style="western"><surname>Kaper</surname><given-names>J.B.</given-names></name><etal/></person-group><article-title>Safety, immunogenicity, and excretion pattern of single-dose live oral cholera vaccine CVD 103-HgR in Peruvian adults of high and low socioeconomic levels</article-title><source>Infect. Immun.</source><year>1993</year><volume>61</volume><fpage>3994</fpage><lpage>3997</lpage><pub-id pub-id-type="doi">10.1128/IAI.61.9.3994-3997.1993</pub-id><pub-id pub-id-type="pmid">8359923</pub-id><pub-id pub-id-type="pmcid">PMC281106</pub-id></element-citation></ref><ref id="B123-vaccines-09-00162"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lagos</surname><given-names>R.</given-names></name><name name-style="western"><surname>Fasano</surname><given-names>A.</given-names></name><name name-style="western"><surname>Wasserman</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Prado</surname><given-names>V.</given-names></name><name name-style="western"><surname>San Martin</surname><given-names>O.</given-names></name><name name-style="western"><surname>Abrego</surname><given-names>P.</given-names></name><name name-style="western"><surname>Losonsky</surname><given-names>G.A.</given-names></name><name name-style="western"><surname>Alegria</surname><given-names>S.</given-names></name><name name-style="western"><surname>Levine</surname><given-names>M.M.</given-names></name></person-group><article-title>Effect of small bowel bacterial overgrowth on the immunogenicity of single-dose live oral cholera vaccine CVD 103-HgR</article-title><source>J. Infect. Dis.</source><year>1999</year><volume>180</volume><fpage>1709</fpage><lpage>1712</lpage><pub-id pub-id-type="doi">10.1086/315051</pub-id><pub-id pub-id-type="pmid">10515838</pub-id></element-citation></ref><ref id="B124-vaccines-09-00162"><label>124.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hughes</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Amadi</surname><given-names>B.</given-names></name><name name-style="western"><surname>Mwiya</surname><given-names>M.</given-names></name><name name-style="western"><surname>Nkamba</surname><given-names>H.</given-names></name><name name-style="western"><surname>Tomkins</surname><given-names>A.</given-names></name><name name-style="western"><surname>Goldblatt</surname><given-names>D.</given-names></name></person-group><article-title>Dendritic cell anergy results from endotoxemia in severe malnutrition</article-title><source>J. Immunol.</source><year>2009</year><volume>183</volume><fpage>2818</fpage><lpage>2826</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.0803518</pub-id><pub-id pub-id-type="pmid">19625645</pub-id></element-citation></ref><ref id="B125-vaccines-09-00162"><label>125.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pasetti</surname><given-names>M.F.</given-names></name><name name-style="western"><surname>Levine</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Sztein</surname><given-names>M.B.</given-names></name></person-group><article-title>Animal models paving the way for clinical trials of attenuated <italic toggle="yes">Salmonella enterica</italic> serovar Typhi live oral vaccines and live vectors</article-title><source>Vaccine</source><year>2003</year><volume>21</volume><fpage>401</fpage><lpage>418</lpage><pub-id pub-id-type="doi">10.1016/S0264-410X(02)00472-3</pub-id><pub-id pub-id-type="pmid">12531639</pub-id></element-citation></ref><ref id="B126-vaccines-09-00162"><label>126.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>B.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Ou</surname><given-names>B.</given-names></name><name name-style="western"><surname>Duan</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>G.</given-names></name></person-group><article-title>Targeting ideal oral vaccine vectors based on probiotics: A systematical view</article-title><source>Appl. Microbiol. Biotechnol.</source><year>2019</year><volume>103</volume><fpage>3941</fpage><lpage>3953</lpage><pub-id pub-id-type="doi">10.1007/s00253-019-09770-7</pub-id><pub-id pub-id-type="pmid">30915504</pub-id></element-citation></ref><ref id="B127-vaccines-09-00162"><label>127.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wilson</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>Hruby</surname><given-names>D.E.</given-names></name></person-group><article-title>Commensal bacteria as a novel delivery system for subunit vaccines directed against agents of bioterrorism</article-title><source>Adv. Drug Deliv. Rev.</source><year>2005</year><volume>57</volume><fpage>1392</fpage><lpage>1402</lpage><pub-id pub-id-type="doi">10.1016/j.addr.2005.01.015</pub-id><pub-id pub-id-type="pmid">15935879</pub-id><pub-id pub-id-type="pmcid">PMC7125890</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="vaccines-09-00162-f001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Homeostasis and inflammation in the gastrointestinal tract. (<bold>A</bold>) The steady state condition of the gastrointestinal immune system is tolerogenic, a baseline condition referred to as homeostasis, in which commensal bacteria are prevented from access to deep tissues but are not actively cleared from the gastrointestinal tract. During homeostasis, resident M2 macrophages maintain a low level of activity, and the T<sub>reg</sub>/T<sub>h</sub>17 ratio favors T<sub>regs</sub>. During homeostasis, potential pathogens such as Enterotoxigenic <italic toggle="yes">Bacteroides fragilis</italic> (ETBF) are present as commensal organisms amongst the normal flora of the gastrointestinal tract. (<bold>B</bold>) Unknown environmental signals can activate secretion of a metalloprotease enterotoxin called <italic toggle="yes">Bacteroides fragilis</italic> toxin, or BFT, leading to loss of commensalism and damage of the colonic epithelial barrier through enzymatic cleavage of epithelial tight junctions. <italic toggle="yes">B. fragilis</italic> neuraminidase [<xref rid="B24-vaccines-09-00162" ref-type="bibr">24</xref>] breaks down the mucus layer to allow deeper penetration of both BFT and the pathogen itself. Invasion of the lamina propria triggers the activation of dendritic cells and shifts the balance of T<sub>reg</sub>/T<sub>h</sub>17 to now favor T<sub>h</sub>17 cells and an inflammatory response. Breach of the intestinal barrier can lead to secretory diarrhea, inflammatory colitis, and extraintestinal infections. For clarity, B cells, ILCs, and other potentially relevant immune cells have been omitted.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="vaccines-09-00162-g001.jpg"/></fig><table-wrap id="vaccines-09-00162-t001" orientation="portrait" position="float"><object-id pub-id-type="pii">vaccines-09-00162-t001_Table 1</object-id><label>Table 1</label><caption><p>Clinical trials of oral immunization with attenuated <italic toggle="yes">Salmonella enterica</italic> serovar Typhi attenuated carrier vaccines expressing foreign (heterologous) antigens.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Vaccine <bold><sup>A</sup></bold></th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Year(s) of<break/>Clinical Trial</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Parent Strain;<break/>Relevant Genotype</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Foreign Antigen</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Expression (Stabilization) Method <italic toggle="yes"><sup>&#8225;</sup></italic></th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">CFU Per Dose; Number of Doses <bold><sup>#</sup></bold></th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Foreign Antigen&#8212;Specific Igg Sero-<break/>Conversion Rates</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Heterologous Booster Given? (Route) <bold><sup>B</sup></bold></th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Ref</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5076-1C w/ plasmid</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1984, 1987, 1990</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ty21a; Str <sup>R</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">Shigella sonnei</italic> O-antigen</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">P (ND)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">~10<sup>9</sup>; 3 doses</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">28/77</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NO</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B2-vaccines-09-00162" ref-type="bibr">2</xref>,<xref rid="B3-vaccines-09-00162" ref-type="bibr">3</xref>,<xref rid="B4-vaccines-09-00162" ref-type="bibr">4</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">EX645 w/ plasmid</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1990</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ty21a; &#916;<italic toggle="yes">thyA rfa</italic><sup>Ty2</sup>::<italic toggle="yes">rfa<sup>E. coli</sup></italic> Rif<sup>R</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">O-antigen from <italic toggle="yes">Vibrio cholera</italic> O1 serotype Inaba</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">P (<italic toggle="yes">thyA</italic>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">~10<sup>10</sup>; 3 doses</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1/14</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NO</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B5-vaccines-09-00162" ref-type="bibr">5</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CVD 908</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1994</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ty2; &#916;<italic toggle="yes">rpoS</italic> &#916;<italic toggle="yes">aroC</italic> &#916;<italic toggle="yes">aroD</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">csp</italic>
<bold><sup>1</sup></bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C (NR)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5 &#215; 10<sup>7</sup>; 2 doses</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2/10</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NO</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B6-vaccines-09-00162" ref-type="bibr">6</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#967;4632(pYA3167)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1996</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ty2; &#916;<italic toggle="yes">cya</italic> &#916;(<italic toggle="yes">crp-cdt</italic>) &#916;<italic toggle="yes">asd</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HBcAg-pre-S1-pre-S2 <bold><sup>2</sup></bold></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">P (<italic toggle="yes">asd</italic>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3 &#215; 10<sup>9</sup>; 3 doses</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0/7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NO</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B1-vaccines-09-00162" ref-type="bibr">1</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CVD 908-<italic toggle="yes">htrA</italic> w/ plasmid</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2000</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ty2; &#916;<italic toggle="yes">rpoS</italic> &#916;<italic toggle="yes">aroC</italic> &#916;<italic toggle="yes">aroD</italic> &#916;<italic toggle="yes">htrA</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">toxC</italic>
<bold><sup>3</sup></bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">P (ND)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10<sup>8</sup> to 10<sup>9</sup>; 1 dose</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3/9</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NO</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B7-vaccines-09-00162" ref-type="bibr">7</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ty1033 w/ plasmid</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2000</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ty2; &#916;<italic toggle="yes">rpoS</italic> &#916;<italic toggle="yes">phoP</italic> &#916;<italic toggle="yes">phoQ</italic> &#916;<italic toggle="yes">purB</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">ureA-ureB</italic>
<bold><sup>4</sup></bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">P (<italic toggle="yes">purB</italic>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&gt;10<sup>10</sup>;<break/>1 dose</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0/7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NO</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B8-vaccines-09-00162" ref-type="bibr">8</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ty21a(pDB1)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2001, 2004</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ty21a; &#916;<italic toggle="yes">thyA</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">ureA-ureB</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">P (<italic toggle="yes">thyA</italic>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">~6&#8211;9 &#215; 10<sup>9</sup>; 3 doses<break/>1&#8211;2 &#215; 10<sup>10</sup>; 3 doses</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0/9<break/><break/>0/9</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NO</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B9-vaccines-09-00162" ref-type="bibr">9</xref>,<xref rid="B10-vaccines-09-00162" ref-type="bibr">10</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TSB7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2007</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ty2; &#916;<italic toggle="yes">rpoS</italic> &#916;<italic toggle="yes">aroC</italic>::P<italic toggle="yes"><sub>ssaG</sub>-eltB</italic> &#916;<italic toggle="yes">ssaV</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">eltB</italic>
<bold><sup>5</sup></bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C (NR)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">~10<sup>8</sup>; 2 doses<break/>~10<sup>9</sup>; 2 doses</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7/12<break/><break/><break/>15/22</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NO</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B11-vaccines-09-00162" ref-type="bibr">11</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CVD 908 w/ plasmid</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2010</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ty2; &#916;<italic toggle="yes">rpoS</italic> &#916;<italic toggle="yes">aroC</italic> &#916;<italic toggle="yes">aroD</italic> &#916;<italic toggle="yes">thyA</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">oprF-oprI</italic> fusion protein <bold><sup>6</sup></bold></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">P (<italic toggle="yes">thyA</italic>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">~10<sup>8</sup>; 1 dose</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">13/16</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">YES (IM)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B12-vaccines-09-00162" ref-type="bibr">12</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ty21a w/ plasmid</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2010</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ty21a; &#916;<italic toggle="yes">thyA</italic></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">oprF-oprI</italic> fusion protein <bold><sup>6</sup></bold></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">P (<italic toggle="yes">thyA</italic>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">~10<sup>10</sup>; 3 doses</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">15/16</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">YES (IM)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B12-vaccines-09-00162" ref-type="bibr">12</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#967;9639(pYA4088) <bold><sup>C</sup></bold></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2013</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ty2; <italic toggle="yes">rpoS</italic>&#8722;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">pspA</italic>
<bold><sup>7</sup></bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">P (<italic toggle="yes">asd</italic>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10<sup>7</sup>&#8211;10<sup>10</sup> in<break/>escalating single doses</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0/20</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NO</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B13-vaccines-09-00162" ref-type="bibr">13</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#967;9640(pYA4088) <bold><sup>C</sup></bold></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2013</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ty2; <italic toggle="yes">rpoS</italic>+</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">pspA</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">P (<italic toggle="yes">asd</italic>)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10<sup>7</sup>&#8211;10<sup>10</sup> in escalating single doses</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0/20</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NO</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B13-vaccines-09-00162" ref-type="bibr">13</xref>]</td></tr></tbody></table><table-wrap-foot><fn><p><bold><sup>A</sup></bold> When provided in publication, the specific expression plasmid is listed; <bold><sup>B</sup></bold> Subjects primed orally with carrier vaccine and then boosted with purified adjuvanted foreign antigen via the intramuscular (IM, adjuvanted with Al(OH)<sub>3</sub>) route; <bold><sup>C</sup></bold> Both 9639 and 9640 carry engineered <italic toggle="yes">araC</italic>-controlled mutations in multiple chromosomal loci, which become attenuating as the carrier vaccine replicates in vivo and diminishes intracellular concentrations of arabinose; <bold><sup>1</sup></bold>
<italic toggle="yes">Plasmodium falciparum</italic> circumsporozoite surface protein; <bold><sup>2</sup></bold> protein fusion of peptide fragments from the hepatitis B virus core protein (HBcAg), pre-S1, and pre-S2 regions of the envelope protein (HBsAg); <bold><sup>3</sup></bold> non-toxigenic fragment C of tetanus toxin; <bold><sup>4</sup></bold>
<italic toggle="yes">Helicobacter pylori</italic> urease subunits A and B. Three of these volunteers orally boosted 15 days post carrier vaccine prime with 60 mg recombinant urease plus 2.5 g native purified <italic toggle="yes">E. coli</italic> heat labile toxin (LT) adjuvant; <bold><sup>5</sup></bold> Enterotoxigenic <italic toggle="yes">Escherichia coli</italic> (ETEC) heat-labile enterotoxin subunit B; <bold><sup>6</sup></bold> fusion protein of <italic toggle="yes">Pseudomonas aeruginosa</italic> outer membrane protein F (OprF; residues 190&#8211;342) and outer membrane protein I (OprI; residues 21&#8211;83); <bold><sup>7</sup></bold>
<italic toggle="yes">Streptococcus pneumoniae</italic> surface protein A; <bold><italic toggle="yes"><sup>&#8225;</sup></italic></bold> P, plasmid; C, chromosomal integration; ND; not done; NR; not relevant for chromosomally expressed antigens; <bold><sup>#</sup></bold> colony forming units (CFU) per dose received by volunteer in designated number of doses administered orally. R: Resistance. </p></fn></table-wrap-foot></table-wrap><table-wrap id="vaccines-09-00162-t002" orientation="portrait" position="float"><object-id pub-id-type="pii">vaccines-09-00162-t002_Table 2</object-id><label>Table 2</label><caption><p>Factors potentially affecting foreign-antigen-specific immunogenicity of attenuated <italic toggle="yes">S.</italic> Typhi-based oral carrier vaccines in humans.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Factor</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Potential Problem</th></tr></thead><tbody><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1. Over-attenuation of the carrier strain itself</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Reduced colonization/contact with immune inductive sites</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2. Ability of carrier to elicit humoral, cellular, and/or mucosal immunity</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Failure to elicit biologically relevant foreign-pathogen-specific immunity</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3. Expression level of the foreign antigen; chromosomal versus plasmid-based expression</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Metabolic burden over-attenuates carrier vaccine</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4. Location of the synthesized foreign antigen; cytoplasmic versus surface or exported</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Intracellular degradation of antigen(s) reduces in situ delivery to immune inductive sites</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5. Inherent immunogenicity of the foreign antigen(s)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Insufficient stimulation of biologically relevant immunity</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6. Immunization strategy; dosing, timing, and homologous versus heterologous vaccination</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Insufficient stimulation of biologically relevant immunity</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7. Host intestinal microbiota</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Reduced colonization/contact with immune inductive sites</td></tr></tbody></table></table-wrap></floats-group></article></pmc-articleset>